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Tuberculosis (TB) continues to be one of the challenging public health concerns, both globally and 
locally. According to the World Health Organization (WHO) Global TB Report 2016, there were 
an estimated 10.4 million new cases globally: 56% among men, 34% among women and 10% 
among children. In addition, people living with HIV accounted for 1.2 million (11%) of all new 
TB cases.  
The distribution of TB cases varies widely across the globe with most cases focused on six 
countries, according to the report. The WHO produced the End TB Strategy in 2015 to control the 
disease and identified a set of targets to decrease the incidence of TB. 
Two key factors for a successful program are understanding the epidemiology of TB and having a 
focused control program. This study will mainly focus on a detailed local analysis of the disease 
epidemiology and the revision of a TB control program. 
Methods 
 
This study was conducted using the existing database in the Department of Health, Abu Dhabi 
(DOH), UAE so as to understand the pattern of the disease over a 4-year period (2012-2015) and 
to identify change patterns, high-risk groups and major disease determinants. In addition, the same 
database was used to evaluate the benefits of GeneXpert in screening settings. Finally, a 
comprehensive review and evaluation of the program, using a WHO framework for evaluation of 
a TB control program, was used to understand the advantages of the program and offer 







This work investigates the Tuberculosis disease using local evidence and data in the hope of 
providing guidance to enable policymakers to set strategic directions for better control of 
Tuberculosis. Use of a standardized tool for the program’s evaluation helps provide a clear and 
relatively objective picture.   
The overall rate of TB in Abu Dhabi did showed no major change in the period between 2012-
2015. The total number of TB cases increased over the years, but the burden rate did not change. 
The study highlighted risk factors related to TB and provided detailed baseline data. TB detection 
procedures improved from the period of the introduction of GeneXpert (MTB/RIF) in 2014. The 
evaluation of the TB control program provided  feedback on the positive aspects of the program: 
TB detection and screening of high-risk groups. In addition, the study provided some suggestions 
for improvements such as treating child TB, providing treatment for latent TB cases and improving 
the detection of XDR by recommending the introduction of a central lab for referrals for drug 
sensitivity testing and  second line TB medication. 
 
Conclusions 
The study provided a snapshot of the current program performance and highlighted the main 
strengths of the program such as screening, diagnosis and reporting. In addition the review of the 
program performance based on international framework, provided some suggestions on the way 
forward and the main areas of improvement. 
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Tuberculosis is a global concern due to the large-scale global burden and the challenges 
associated with the disease. It is one of the top 10 causes of death worldwide. According to the 
World Health Organization (WHO) World TB Report 2017, around 10.4 million people fell ill 
with TB during 2016 and around 1.7 million died from the disease. Most TB deaths occur in low 
and middle-income groups where there are issues concerning access to TB treatment. Of the total 
cases reported in that year, 0.4 million cases of TB were of people with HIV and 1 million cases 
were of children. Around 64% of TB cases were concentrated in seven countries: India, 
Indonesia, China, Philippines, Pakistan, Nigeria, and South Africa. 
One of WHO’s targets is to end the global TB epidemic by supporting the End TB Strategy, 
which calls for a 90% reduction in TB deaths and an 80% reduction in the TB burden rate by 
2030 compared with 2014. One of the main indicators for this strategy is the annual burden rate. 
According to the WHO Global Report for 2016, the estimated rate of TB in the UAE is under 
24.9 per 100,000 population (1).  
The first step towards reaching the elimination of TB is to have a good understanding of the 
disease status and baseline of the country. This understanding will help in monitoring both the 
effectiveness of the elimination strategy and the performance of the TB control program. This 
study is focused on understanding the epidemiology of TB, the updates on TB diagnostics and 





Estimating the Burden of Tuberculosis in Abu Dhabi based on the notifications and 
screening of data including all age groups and nationalities for the years 2012 to 2015 
 
This comprehensive review included two main sources of data: electronic notifications and visa 
screening. The objective of this study is to provide a clear understanding of the disease 
epidemiology of TB and to define any high risk groups to guide policymakers in improving the 
existing control program. In considering all cases reported from both systems, it covers the full 
study population including nationals and expatriates of varying age groups. It is consequently 
representative of the actual population. All applicants of the visa screening process are screened 
for TB and, if suspected of having TB, confirmatory testing is then mandatory. The study 
excluded recently arrived expatriates (new immigrants to Abu Dhabi within a one-month period 
of arrival from their home country) as they do not represent the local status and are more 
representative of their country of origin. The study included a review of the rate over time, the 







The evaluation of the benefits of using GeneXpert in the medical screening process for 
visa applications 
 
The objective of this study is to evaluate the benefits of GeneXpert in a screening setting.  The 
review considers data pre- and post- implementation of the test in the visa screening setting for 
confirmation of suspected TB. This is a retrospective study using visa screening data to measure 
the impact of change in the diagnostic modalities used in the program. Prior to the test 
introduction, all suspected cases had to provide sputum smear and culture. The data analysis 
included the calculation of the PPV, NPV, and time for confirmation. This study will provide 
some guidance for the use of geneXpert in screening setting. 
 
Manuscript Three 
Evaluation of TB control program in Abu Dhabi in alignment with the WHO Global 
Strategy using WHO Framework for conducting reviews of Tuberculosis programs. 
 
This manuscript summarizes a comprehensive revision of TB control program components 
including field visits at different levels of the program including the central unit in Department 
of Health, Abu Dhabi, DOH, diagnosis facilities, screening facilities, primary health care settings 
and treatment facilities in both private and public sectors. This study aims to see the extent of 
alignment between the TB control Program in Abu Dhabi and the WHO Global Strategy so as to 
identify key opportunities for improvement based on UAE priorities. This qualitative measure of 
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the program is anticipated to provide guidance to local policymakers to inform revisions in 






Estimating burden of tuberculosis in Abu Dhabi based on the 
notifications and screening data including all age groups and 
nationalities for years 2012 to 2015 
Abstract 
Background  
A full review of TB epidemiology is required to provide a clear understanding of the disease 
determinants and risk factors and help program managers to plan for the disease control based on 
the local data.  
Methods 
The study is descriptive analysis utilizing existing data available in central Department of Health 
for the period from 2012-2015. Two data sources used for the study: Active screening and 
passive reporting. The analysis was done for each dataset separately and then combined the data 
to review main determinants and change over time. Combining both data allowed us to have a 
representation of the whole population with different nationalities and age groups. In addition, 
we calculated age adjusted rates of TB. 
Results 
Total cases of 3507 confirmed TB was identified in the period from 2012 untill 2015. 
The year of 2012 had the highest rate of TB in notifications but no major change in the rate of 
TB over time of in visa screening system. The passive reporting of TB provided more 
information about TB among UAE nationals and children in addition to risk factors. Diabetes 
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and smoking were most prevalent risk factors among TB patients (approximately 8.4% of 
patients reported smoking and 7.6% reported history of Diabetes. Antimicrobial resistance rate 
MDR had a slight deline over time (ranged from .5 per 100,000 in 2012 to .38 per 100,000 in 
2015). The change of TB prevalence rate was very minimal 2013 to 2015 (Age adjusted rate 
ranged between 23.1-25.5 per 100,000) 
Conclusion 
TB is most common among expatriates living in UAE especially those coming from countries 
with high burden of TB. The study provided more details about high risk groups by age, gender 















In 2015, the United Nations adopted Sustainable Development Goals (SDGs) for 2030. One of 
the targets is to end the global TB epidemic by supporting the WHO End TB strategy which calls 
for a 90% reduction in TB deaths and an 80% reduction in the TB burden rate by 2030 compared 
with 2014. One of the main indicators for this strategy is the annual burden rate. According to 
the WHO Global Report, 2016, the estimated rate of TB in the UAE is below 24.9 per 100,000 
population (1). The first step towards reaching elimination is to know the disease status and 
baseline of the country. This will help in monitoring the effectiveness of the elimination strategy 
and the performance of TB control program itself.  
 
Abu Dhabi is the capital of the UAE with a population of around 3 million, approximately one 
third of the total UAE population and around 87% of the total area. This population composition 
includes a unique mix of people coming from both TB endemic areas and countries of with very 
low prevalence of TB. This mix of people imposes a burden on the UAE health care system in its 
attempts to maintain a relatively low level of TB in the country. 
The Health care system in Abu Dhabi is well established. TB is one of the priority diseases 
included in the National and Local level plans. The most recent national annual health report for 
the UAE was published in 2010 and included statistics and data about TB in the country.  In 
2016, the burden rate of TB in the UAE was 1.6 per 100,000 population (range between 1.1-2.1). 
The mortality rate due to TB and HIV was around .32 per 100,000 population. The percentage of 




A search of local publications about the epidemiology of TB revealed two studies. 
The first study was a retrospective epidemiological analysis performed in Al Ain (Eastern Abu 
Dhabi region) (1). The period of analysis was from 1995-2000. The mean burden rate reported 
during this period was 7.1 per 100,000 population: more than three times that reported for the 
period 1983-1992. The study also conducted a genetic analysis for seven isolates and found a 
unique strain in the UAE that did not match >4000 different individual strains (6).  
The second study was conducted in the UAE Emirate of Sharjah to investigate the pattern of TB 
distribution among the northern emirates population for the period 2004-2008. The study 
reviewed around 1,810 samples of suspected TB and found 312 culture-positive TB cases. Most 
cases were seen among South and South East Asian nationalities (36%). Only 16% of cases were 
seen among UAE nationals and more than two-thirds of these cases were males (7). 
 
A regional study done in the Kingdom of Saudi Arabia (KSA) to investigate the trends of TB in 
the kingdom during the period 2005 - 2009 concluded that the rate of TB in non-Saudis was 
twofold higher compared to Saudis (8). 
 
A further example of the impact of immigrants on TB epidemiology is from Sweden. The burden 
of TB is around 5.5 per 100,000. Approximately 10% of the population of Sweden are 
immigrants from 42 different countries. The study considered TB strains during the period 2001-
2005 and found 349 patients, 17%  of whom came from European countries. Around 28% were 
of various African nationalities and 16% came from Asian countries. The study concluded that 
immigration from high burden countries had a greater impact on TB epidemiology than that from 
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the low burden countries and that this should be taken into consideration when planning  TB 
control strategies (9). 
 
The UAE entered a new era of public health electronic surveillance with the establishment of the 
Department of Health Abu Dhabi (DOH) in 2005 as the regulator of the health care system in the 
Emirate of Abu Dhabi and the new establishment of public health within DOH. The current 
system allows the UAE to gather information from various sources to give an indication of the 
burden and prevalence of TB in Abu Dhabi among both national and expatriate populations. One 
of the strengths of the surveillance system for infectious diseases is the ability to access live data 
with automated analysis that provides a live-time report of the current status. This database is 
also a rich source of information for epidemiological studies aiding more understanding of the 
disease, its risk factors and its distribution. 
A careful review of information gathered from the electronic notification system, the main 
source of passive reporting of suspected and confirmed cases in public and private hospitals, 
helped estimate the burden of TB in Abu Dhabi. In addition, the active annual screening of all 
expatriates (newcomers and renewals) was used as another important source of data. 
To achieve a reduction in the rate of Tuberculosis in Abu Dhabi and the UAE in general, the 
epidemiology of the disease must be studied. Trends must also be understood as well as 
determinants and risk factors associated with the disease. This study is conducted to provide 
policymakers with a comprehensive overview of the burden of TB in Abu Dhabi utilizing 






The study utilized two existing databases for TB in Abu Dhabi: Infectious Diseases Notification 
and the Visa Screening System. Detailed case information was also available and included 
patient demographics, clinical information, and lab results. The study covered all records 
available from January, 2012 until December, 2015. Notifications processed in the electronic 
system are reviewed and verified by the TB team. Should any case fail to fulfil the definition 
criteria of TB, it is excluded from the system. The population data obtained from the DOH 
database includes age, gender, nationality for the period 2012-2015. 
The case definitions used in this study are the WHO standard case definitions (10): 
“a bacteriologically confirmed TB case is one from whom a biological specimen is positive by 
smear microscopy, culture or WRD (such as Xpert MTB/RIF).  A clinically diagnosed TB case 
is one who does not fulfil the criteria for bacteriological confirmation but diagnosed with active 
TB by a clinician or other medical practitioner who has decided to give the patient a full course 
of TB treatment.  This definition includes cases diagnosed based on X-ray abnormalities or 
suggestive histology and extra-pulmonary cases without laboratory confirmation.  
Pulmonary tuberculosis (PTB) refers to any bacteriologically confirmed or clinically diagnosed 
case of TB involving the lung parenchyma or the tracheobronchial tree. Military TB is classified 
as PTB because there are lesions in the lungs. Tuberculous intra-thoracic lymphadenopathy 
(mediastinal and/or hilar) or tuberculous pleural effusion, without radiographic abnormalities in 
the lungs, constitutes a case of extra-pulmonary TB. A patient with both pulmonary and extra-
pulmonary TB classified as a case of PTB.  
11 
Extra-pulmonary tuberculosis (EPTB) refers to any bacteriologically confirmed or clinically 
diagnosed case of TB involving organs other than the lungs, e.g. pleura, lymph nodes, abdomen, 
genitourinary tract, skin, joints and bones, meninges.
Multidrug-resistant tuberculosis (MDR-TB) is a form of TB caused by bacteria that do not respond 
to isoniazid and rifampicin, the 2 most powerful, first-line anti-TB drugs. Extensively drug-
resistant tuberculosis (XDR-TB) is a form of TB, which is resistant to at least four of the core anti-
TB drugs. XDR-TB involves resistance to the two most powerful anti-TB drugs, isoniazid and 
rifampicin, in addition to resistance to any of the fluoroquinolones (such as levofloxacin or 








List of Variables Used 
The initial analysis was done for each dataset separately and included a list of variables shown in 
Appendices 1 and 2. Matching of the common variables was done to match both datasets. The 
nationality group was created to merge groups of countries based on WHO region distributions.  
 
Data Analysis 
Data analysis was conducted using STATA and SPSS software. Notifications data were revised 
for completeness and data quality. 
Exclusion Criteria 
The exclusion for the cases that included the field (Discard reason) was done based on case 
definition. Cases reviewed in the central unit of DOH and confirmed as TB were excluded. 
Reasons for discarding were stated in the database. The principal reasons for exclusion were 
changing the diagnosis to other conditions or duplication (as records was separately available in 
the visa screening dataset). This additional point of check provided a higher quality of data.  
In the visa screening database, incomplete suspected cases were excluded to ensure the quality of 
case definition. 
 
Analysis by Nationality 
Due to the long list of nationalities observed in the database, the grouping of countries was done 
based on WHO regions. This was important to simplify the analysis and to ameliorate 
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comparison to published WHO data. Simple frequency count of positive cases was done after 
grouping. The grouping of countries was: 
1. Africa  
2. Americas  
3. South-East Asia  
4. Europe  
5. Eastern Mediterranean  
6. Western Pacific  
 
Visa Screening Data 
Analysis of Visa screening results consisted of trend over time, frequency, and tabulations. A 
comparison between new rates and renewals rates of TB was carried out. In addition, a 
calculation of mean and median values for different variables was included. A review of Visa 
Screening applicants based on residency status (newcomers versus renewals) was important as 
previous research had confirmed a major difference in TB rates between both types. 
 
E-Notification Data 
The analysis of pulmonary TB notifications and Extra-pulmonary notifications was conducted 
for each dataset separately. It included a review of data quality, the completeness of fields and 
the selection of appropriate fields in the analysis. Frequencies, the distribution of age groups and 
nationalities were then calculated. It is important to highlight that the method of passive 
reporting from hospitals included additional clinical details to that of the visa screening data, 
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such as risk factors, drug resistance and previous history of the disease. Although not all fields 
were fully completed, most cases consisted of a sufficient list of required variables.   
Combined Data 
To estimate the burden of TB in Abu Dhabi, it was necessary to exclude newcomers as it was 
considered that they reflected the TB rates in their country of origin rather than in the Abu Dhabi 
population. The method of calculation is shown in Figure 2. The basic variables of age, gender, 
nationality and diagnosis provided one set of data for analysis of all age groups and nationalities 
represented in the Abu Dhabi population. Further analysis was carried out to identify the total 
population and calculate both crude rates and age adjusted rates. An age standardized calculation 
was done based on WHO standards (14).  In addition, a calculation of mean age over time was 
carried out to examine the change in the population infected with TB. 
 








Section A  
Active Screening of Expatriates 
During the period from January, 2012 to December, 2015,  2,235 confirmed cases of TB were 
identified through the Visa Screening System. Most cases diagnosed were among newcomers 
(69.8% of the total TB cases). Table 1 shows the main difference between new and renewal 
groups according to age, gender, nationality group and occupation.  
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The mean age for newcomers diagnosed with TB was around 40 years, which is very similar to 
the renewal group. In addition, most of the affected cases were males (82.7% from newcomers 
and 86.5% from renewals).  
In considering the nationality group, most of the affected cases emanated from South East Asia, 
followed by the Middle East. The least affected group was America. 
 
Table 1. Summary of Visa Screening positive TB by residency status 2012-2015 (n=2235) 
  New Renew Total 
  N % N %   
Age years Mean) 40   39.1     
Gender   
Female 267 17.3% 94 13.5% 361 
Male 1275 82.7% 603 86.5% 1878 
Nationality 
Group*   
Middle East 544 35.3% 180 25.8% 724 
South East Asia 730 47.3% 400 57.4% 1130 
Africa 64 4.2% 24 3.4% 88 
Europe 8 0.5% 2 0.3% 10 
Western pacifica 195 12.6% 91 13.1% 286 






A 1216 78.9% 588 84.4% 1804 
Bi 215 13.9% 78 11.2% 293 
Bii 111 7.2% 31 4.4% 142 
            
Year   
2012 327 21.2% 126 18.1% 453 
2013 289 18.7% 212 30.4% 501 
2014 407 26.4% 112 16.1% 519 
2015 519 33.7% 247 35.4% 766 
 
TB Annual Incidence Rate 
The annual burden rate appeared to show differences between both groups. The annual burden 
rate of TB among newcomers ranged between 55-68 per 100,000 population, relatively higher 
than the rate of TB among renewals, which ranged between 24-43 per 100,000 population. The 
overall rate of TB between both groups showed no major change over the period of study (4 
years). It is very hard to estimate how much of renewal population is new case or, latent 
reactivation due to absence of this information in the system. Renewal population screened 








Most cases were confirmed either by Culture or the GeneXpert test used from 2014 onwards. 
Prior to this period, all suspected cases of TB had positive culture results. In the year 2015, 
around 55% of the total positive cases were confirmed using GeneXpert. 
 
Section B
Passive Reporting of TB 
During the period from January, 2012 to December, 2015,  2,810 TB cases were confirmed in 
Abu Dhabi from both private and public hospitals. This total included 1,982 notifications of 
pulmonary TB and 828 extra-pulmonary TB. Figure 4 shows the number of notifications by type 









2012 2013 2014 2015
Burden rate of TB cases detected during Visa screening process 
case per 100,000 population
Rate total Rate Renew Rate New
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of discarded cases (only one case). This result might indicate some data quality issues. The 
number of cases reported with pulmonary TB was higher than that reported with extra-
pulmonary TB. 
Figure 4: Number of TB cases reported by the E-Notification system during 2012-2015 (n=2810) 
 
 
The reported cases included varying age groups and included children under 4 years of age. The 
data are an important source of information concerning children. Figure 4 shows a summary of 
TB cases by age group. Extra-pulmonary TB is more common in children under 15 years of age 









2012 2013 2014 2015
Reported Cases of Tuberculosis and Extra-
Pulmonary TB over time
Pulmonary TB Extra-Pulmonary TB
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Figure 5: Number of TB cases reported by the E-Notification system during 2012-2015 by age groups 
(n=2810) 
 
Risk Factors Associated with TB 
Risk factors associated with the disease are shown in Figure 6. Approximately 8.4% of patients 
reported with TB (including both pulmonary and extra-pulmonary) were smokers. In addition, 
around 7.6% of patients had a history of diabetes. HIV is one of the known risk factors of TB 






















The database included results of antimicrobial resistance. Figure 7 shows the details of drug 
resistance over time. It is clear from the Figure that 2014 shows a majority of MDR cases (15 
cases in the same year). The number of cases tested increased over time and the percentage of 








In addition, the rate of TB MDR shows a slight decline over time starting with 0.5 per 100,000 
population in 2012. The rate by 2015 was 0.38 per 100,000 population. 
 
Table 2 Summary of MDR and XDR status from notified cases 2012-2015 








Total cases Total 
Tested 
MDR rate/100,000 
2012 10 3 13 86 0.50 
2013 12 0 12 92 0.44 
2014 15 0 15 114 0.54 
2012 2013 2014 2015
MDR case 13 12 15 12































MDR Cases and percentage over time
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2015 11 1 12 156 0.38 
Total 




Figure 8: Drug resistance Type reported from Pulmonary and Extra-Pulmonary TB case (2012-2015)  
 
Figure 8 shows the most common types of medication tested for susceptibility. Isoniazid is the 
most common type of drug with a resistance level of 8.8%. Resistance to second line medication 
is also reported: approximately 8.5% of cases tested were found to have resistance. There is 
insufficient data to comment on XDR: data were available from only two medications of second 
line treatment and remaining data were missing. 







Isoniazid Rifampicin Pyrinzinamide Ethambutol Streptomycin Ethionamide
% 8.8% 5.4% 7.6% 3.8% 8.5% 40%
susciptable 430 448 448 444 366 15
Resistant 38 24 34 17 31 6




Around 8% of the cases reported had a previous history of TB diagnosis, which possibly 
indicates a relapse or previous incomplete treatment. Moreover, around 6.3% of cases reported 
previous treatment for TB. 
Table 3 History of Previous TB diagnosis and TB treatment 






11 60 83 72 226 8.0% 
TB previous 
Treatment 
6 51 68 52 177 6.3% 
 
Section C 
Combined Data and Calculation of TB Burden 
The Emirate of Abu Dhabi reported 3,350 new tuberculosis cases during the period 2012 to 
2015. Analysis of the figures indicated a 52% decrease from 1,352 TB cases reported in 2012 to 
654 cases reported in 2015 (see Figure 1). Similarly, the TB crude incident rate showed a 




Figure9: Tuberculosis cases and rates by year 2012-2015 
 
 
TB in Abu Dhabi occurred predominantly among males (2,597 cases, 77.5%), compared to 
females (753 cases, 22.5%). TB occurred in all age groups, but the most affected age groups 
were 25-44 year olds (1,707 cases, 51.0%) and 45-64 year olds (877 cases, 26.2%). Children, 
teenagers or young adults were the least affected age group of TB cases (see Table 1). 
Nationalities in Abu Dhabi were disproportionately affected by TB. Expatriates accounted for 
94.2% of TB cases compared to UAE nationals (5.8%). 
 
Table 4. Tuberculosis Cases and Percentage by Gender, Nationality, and Age Group (2012-2015 
(n=3507) 
Demographic  Frequency % 
Total 3507 100.0% 
Gender 
2012 2013 2014 2015
# Cases 1346 694 655 812































Abu Dhabi Tuberculosis Cases and Rates by Year, 2012-2015  
(n=3507)
# Cases Crude  rate
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Male 2738 78.1% 
Female 769 21.9% 
Age Group     
0-4 23 0.7% 
5-14 20 0.6% 
15-24 392 11.2% 
25-44 1812 51.7% 
45-64 913 26.0% 
>=65 347 9.9% 
Nationality 
UAE National 3312 94.4% 
Expatriate 195 5.6% 
 
 
From 2012–2015, the age-adjusted rates of TB cases declined by 84.5%: from 130.6 per 100,000 
in 2012 to 25.5 per 100,000 population in 2015. Among the 3,507 TB cases in Abu Dhabi, 
Routine Surveillance reported a higher number of TB cases (1,982) compared to Visa Screening 
(697). The routine surveillance TB cases (1,982, 56.5%) were all pulmonary tuberculosis cases. 
In 2015, the burden rate for males versus females was 26.8 per 100,000 population (male) to 20.7 
per 100,000 population (female). Comparing UAE nationals with expatriates, a higher 




Table 5: Summary of total cases reported from notifications and visa screening (n=3507)  











Rate of TB ( 
per 100,000 )  
95% confidence 
interval 






40.0   32.9   39.1         
Gender**       
Female 448 22.6 227 27.4 78 14.8% 20.7 17.6 23.8 
Male 1534 77.4 601 72.6 462 85.2% 26.8 24.8 28.9 
Nationality 
Group* 
      
EMRO 692 39.1% 282 37.2 258 37.5% N/A N/A N/A 
SEARO 961 54.3% 440 58.7 396 58.8% N/A N/A N/A 
AFRO 117 6.6% 30 4.0 20 3.7% N/A N/A N/A 
Nationality 
status** 
      
UAE 
(National) 
132 6.7 63 7.6 0 0 7.9 5.0 10.7 
Expatriates 1850 93.3 765 92.4 540 100 29.9 27.8 32.0 
Year                   
2012 996 50.3 224 27.1 126 18.1% 130.6 123.6 137.5 
2013 311 15.7 171 20.7 212 30.4% 26.8 24.8 28.8 
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2014 338 17.1 205 24.8 112 16.1% 23.1 21.4 24.9 
2015 337 17.0 228 27.5 247 35.4% 25.5 23.8 27.3 
 
* Only top 3 WHO region countries cases and percentages      
** Rate equals only 2015 cases     
N/A= Total denominator data not available     
 
Table 6. Tuberculosis Cases Mean Average Age by Gender and Year (n=3507) 
Gender 2012 2013 2014 2015 
Female 53 35 36 38 
Male 54 37 37 36 
 
In addition, the mean average age of cases affected with TB ranged between 35-38 during the 
2013-2015 with only a minor variance between males and females. The mean average age in 





This study provided a comprehensive overview of TB in Abu Dhabi using all available data from 
various programs to gain a better understanding of TB status and the change thereof over time.  
It is clear from the study that the prevalence rate of TB among the local population compared to 
expatriates is low, the age adjusted rate for UAE nationals being 7.9 per 100,000 compared to 
29.9 per 100,000 for UAE expatriates.  
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Screening for TB among high risk groups is one of the important tools for a TB control program. 
The estimate is consistent with the WHO global report, 2016 which considered the burden rate of 
TB in United Arab Emirates as low (burden between 0-24 per 100,000) (1). 
The focus on immigrant population in terms of screening for TB and early detection is known 
practice in countries with a low TB burden, especially for immigrants coming from countries 
with a high incidence rate of TB. A study conducted in Spain confirmed that TB is the most 
common infection detected among immigrants coming from Sub-Saharan Africa and North 
America (14). Among the expatriate population, it is clear most cases are detected in newcomers 
compared to the resident population. This might reflect a higher incidence of TB in the country 
of origin, but outbreaks can be prevented by strengthening home screening. 
The study describes a higher rate of TB in males compared to females. The male to female ratio 
is around 3.5:1. In addition, it is clear from the age group distribution that TB is more common 
in the young population between 25-44 years of age, which is not in line with the WHO Global 
Report 2016. Only few countries in Africa, specifically Nigeria and Zambia, had higher rates of 
TB among young adults whereas most of Asian countries had higher rates of TB among the 
elderly population. This might reflect the population proportion since the majority of the working 
force are young and coming from countries with high rates of TB. It might also reflect the fact 
that higher transmission rates are found in the young adult population and lower rates of 
transmission are found in the elderly population. It is clear from the results that young adults and 
children are more likely to present with extra-pulmonary TB compared to older adults. 
The active screening of expatriates provides a high yield of detection compared to notification, 
which is useful for early detection and management. Screening is worth doing: significant 
benefits include the early identification of risk groups, possible timely 
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treatment/chemoprophylaxis intervention, and the prevention of transmission by significantly 
reducing infectiousness with subsequent avoidance of hospitalization (44). 
The study of TB rates over time showed no major change during the period of study 2012-2015. 
The number of notifications for pulmonary TB in 2012 was very high for unexplained reasons 
and the rate of TB with multi-drug resistance in the same year was higher compared to 
subsequent years. However, from the screening data, there was no similar finding. The range was  
between 37 to 42 per 100,000. The TB crude rate decreased from 52.4 cases per 100,000 
population in 2012 to 25.8 cases per 100,000 population in 2015. This might be due to the higher 
rates of pulmonary TB notifications in year 2012. A study of tuberculosis burden for the Al Ain 
Medical District showed a burden of tuberculosis in the UAE which increased from 18.9 cases 
per 100 000 population in 1989 to 28 cases per 100 000 population in 1998 (9). 
 
The study also confirms common risk factors associated with the disease: smoking, diabetes and 
HIV. Smoking ranked top of all risk factors commonly found among cases of TB. 
The data about TB MDR show a slight decline over time starting with 0.5 per 100,000 
population in 2012. By 2015, it was 0.38 per 100,000 population: much less than the previous 
rates published in other studies. In reviewing similar local studies, there was study in Al Ain 
which described evidence of ‘emerging’ multidrug-resistant M. tuberculosis strains in the Al Ain 
Medical District, UAE. Incidence increased from 1.4% in 1997-1998 to 8.5% in 1999-2000(9). 
Another Study of TB in Sharjah, UAE reported rates of TB MDR to be around 3.8% (10). Recent 
datasets examined show a decline in the resistance rate for the period 2012-2015 where in 2012 
there was around 14% of positive samples showing MDR. By the end of 2015, only 8% of the 
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total tested showed TB MDR. The study of XDR was limited in this study because of the small 
number of cases tested for second line medication sensitivity. 
Limitations of the study included missing TB treatment coverage data that could have provided 
additional information about the program performance and outcome of cases. The study 
excluded patient geographic location to highlight specific locations of high risk. The study of 
patient outcome was a very important element of TB management effectiveness. The 
methodology of the study included the elimination of duplicated files between the two datasets, 
but did not take into consideration the reporting of the same case in subsequent years which 




In summary, this is the first comprehensive review of local TB data to estimate the burden of TB 
in Abu Dhabi. There are very limited studies which have been done in the United Arab Emirates 
and in the Gulf Region to study the disease determinants and the trend of the disease over time. 
The main objective of this study was to provide a holistic view of the disease in the Emirate of 
Abu Dhabi using existing datasets to provide the local authority with a better understanding of 
high-risk groups, risk factors and the trend of the disease over time. 
The results of the study showed a slight decline in the rate of TB over the period of 4 years from 
2012-2015. The most affected groups were newcomers arriving to work and reside in Abu 
Dhabi. Among the resident population, the young adult male working population from areas of 
high rates of TB seemed to have the highest rate of TB. The drug resistance pattern was in slight 
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decline over time. Smoking was the top risk factor of the disease. TB/HIV cases were limited in 
the population studies.  
 
We recommend further study of MDR/XDR rates and a more systematic testing for cases 
diagnosed with TB. In addition, further studies of the TB DOT program performance might be 

















APPENDIX 1 – List of variables used in Visa screening system 
Variable Name Label & Units Format Codes 
Year Year of test yyyy  
APP_NO Number of specific code for each 
applicant of visa screening. It is a 
unique number for each encounter 
with visa screening 




Nationality of visa screening 
applicants. Each country is 
mentioned 
Nationality list  
None 
 









Date of birth Date of birth of applicants Date: dd/mm/yyyy None 
Age Age in years number =INT(YEARFRAC(E3; 
K3)) 
VISA TYPE New or renew in the country text New or Renew 
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GENDER Male or Female text Male or female 
APPLICANT 
OCCUPATION 
Occupation of the applicant text List of occupations 
APPLICANT 
CATEGORY 





START DATE Date of testing date Dd/mm/yyyy 
RAD_OBSERVATION_1 The CXR reading by the first 
radiologist 
Text/number PH030 Normal 
PH031 Abnormal not 
PTB 
PH032 Old PTB 
PH033 High suspicion 
active PTB 
PH034 Medium 
suspicion active PTB 
PH035 low suspicion 
active PTB 
RAD_OBSERVATION_2 The CXR reading by the second 
radiologist 
Text/number PH030 Normal 




PH032 Old PTB 
PH033 High suspicion 
active PTB 
PH034 Medium 
suspicion active PTB 
PH035 low suspicion 
active PTB 
RAD_OBSERVATION_3 The CXR reading by the third 
radiologist 
Text/number PH030 Normal 
PH031 Abnormal not 
PTB 
PH032 Old PTB 
PH033 High suspicion 
active PTB 
PH034 Medium 
suspicion active PTB 
PH035 low suspicion 
active PTB 
AFB SMEAR 1st AFB smear results first sample Text/number PH040 0 per 300 fields 
PH041 1 per 300 fields 






AFB SMEAR 2nd AFB smear results second sample Text/number PH040 0 per 300 fields 
PH041 1 per 300 fields 




AFB SMEAR 3rd AFB smear results third sample Text/number PH040 0 per 300 fields 
PH041 1 per 300 fields 












TB CULTURE 3rd Culture results 3rd  sample Text/number PH238 No growth 
PH239 MTB 




RIF Rifampicin resistance   
TST Tuberculin skin test number From 1 to 10  
Note some used 
number then mm  
IGRA IGRA results Text/number PH197 
PH198 
PH199 
ACTION ID Results of the certificate fit or unfit number -1 incomplete results 
4  Active TB unfit 
5  Old PTB unfit 
9  pending results 
11 previously unfit case 
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NEW ACTION ID Revised results by the team action is 
changed 
number 1 fit 
2 fit and follow up 
3  
4 Active PTB unfit 
5 old ptb unfit 
HIV ACTION HIV final action based on results of 
HIV 
number -1 incomplete 
1  HIV negative fit 
4  HIV positive unfit 
HBV ACTION final action based on results of 
Hepatitis B 
number --1 incomplete 
0 test not required 
1  HBV negative fit 
5  HBV positive unfit 
SYP ACTION 
 
 final action based on results of 
Syphilis 
number 0 test not required 
1  Syphilis negative fit 
3  Syphilis unfit 
CXR ACTION 
 
 final action based on results of TB number 4 Active ptb 
5 old ptb 





APPENDIX 2 – List of Variables used in notification system 
Variable Name Label & Units Format Codes 
year Year of test yyyy none 
CASE_ID 
 
Number of specific code for 
each notification. It is a 
unique number for each 
encounter with visa screening 
Text & Numbers None 
DOB 
Date of birth of applicants Date: dd/mm/yyyy  
CI_Age 
Calculated age numbers  
Nationality Nationality of patient. Each 
country is mentioned 
Qualitative variable  
 
 

















city of residence of the patient number  
CITY_TITLE 
 
city of residence of the patient text  
EI_OCCUPATION 
 
Occupation of patient number  
OCCUPATIONNAME_EN 
 
Occupation of patient text  
EI_RESIDENCESTATUS 
 




CLI_DIAGNOSIS Clinical diagnosis text  
CLI_SUSBECTED Suspected or confirmed Text  Suspected 
Confirmed 
CLI_DATEOFONSET Date of onset date dd/mm/yyyy 
CLI_PATIENT Inpatient or outpatient text Inpatient 
outpatient 





NAME_EN Hospital or facility name text  








GENDER Patient gender text Male 
female 
DISCARD_REASON Will be filled only if the case 
is discarded from the records 
text  
MAJOR_DISEASE_SITE Type of the disease text  
TESTING_REASON 
 









SYMPTOMS Patient presenting symptoms text options 
SYMPTOMS_OTHER Other symptoms text options 












CT_SCAN_RESULT CT scan results text  





TB_DIAGNOSIS_PREV_YAER Year of previous diagnosis number  





TB_TREATMENT_PREV_YEAR Year of previous treatment number  
TB_TREATMENT_PREV_DURATION Duration of previous treatment number  





TB_CONTACT_PREV_YEAR Year of contact with previous 
case 
year  
BCG_VACCINE_HISTORY History of BCG vaccine number 0 
1 
2 
BCG_SCAR_PRESENT Presence of BCG vaccine scar number 0 
1 
2 
RISK_FACTOR Risk factors text options 
RISK_FACTOR_OTHER Other risk factors text Free text 
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SPUTUM_SMEAR1 AFB results text Not done 
Negative 
positive 
SPUTUM_SMEAR2 AFB results Text Not done 
Negative 
Positive 
SPUTUM_SMEAR3 AFB results text Not done 
Negative 
positive 
TB_PCR_TEST_RESULT PCR result Text/ number -1 
Not done  
Negative 
positive 
TST Tuberculin Skin Test number  
IGRA_TEST IGRA results Text/ number -1 
Not done  
Negative 
positive 
HIV_TEST_RESULT HIV results Text/ number -1 
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Not done  
Negative 
positive 













DRUG_SUS_ISNONIAZID Susceptibility to drugs text Resistant 
susceptible 




DRUG_SUS_PYRAZINAMIDE Susceptibility to drugs text Resistant 
susceptible 
DRUG_SUS_ETHAMBUTOL Susceptibility to drugs text Resistant 
susceptible 
DRUG_SUS_STREPTOMYCIN 
Susceptibility to drugs text Resistant 
susceptible 
DRUG_SUS_ETHIONAMIDE Susceptibility to drugs text Resistant 
susceptible 
DRUG_SUS_CAPREOMYCIN Susceptibility to drugs text Resistant 
susceptible 
DRUG_SUS_AMIKACIN Susceptibility to drugs text Resistant 
susceptible 
DRUG_SUS_RIFABUTINE Susceptibility to drugs text Resistant 
susceptible 
DRUG_SUS_STREPTOMYCIN Susceptibility to drugs text Resistant 
susceptible 
DRUG_SUS_CIPROFLOXACIN 




DRUG_SUS_OFLOXACIN Susceptibility to drugs text Resistant 
susceptible 
DRUG_SUS_OTHER1 Susceptibility to drugs text Resistant 
susceptible 
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The implementation of the GeneXpert test for tuberculosis in the visa screening 




Advances in diagnostic technologies in the last decade have dramatically affected health care in 
many ways. Diseases that used to be difficult to diagnose, such as tuberculosis (TB), and the 
confirmation process took weeks due to the complexity of identification. Today, sensitivity 
testing has become simplified and now can be completed in days or hours. Tuberculosis is a 
challenging disease that is considered to be a global epidemic. According to the WHO Global TB 
Report, 2017, TB continues to be a high burden disease characterized by insufficient progress to 
reach its set targets. TB is the ninth leading cause of death world-wide and the leading cause 
from a single infectious agent, ranking above HIV/AIDS (1). In the year 2016, around 1.3 people 
died from TB among HIV negative persons and around 374,000 deaths were attributable to co-
infection with HIV. Around 10.3 million people are estimated to have become infected with TB 
and around half of them were concentrated in five countries: India, Pakistan, Indonesia, China 
and the Philippines (1). 
 
Drug resistance to TB continues to be a challenge in terms of treatment. In 2016 alone, 
approximately 600,000 cases of rifampicin resistance were reported and most were multi-drug 
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resistant (MDR) (1). Identifying resistance early enough to start the right treatment is important 
to control the transmission of the disease. 
 
The history of identification of Mycobacterium Tuberculosis and the advances in diagnosis has 
been well documented. A German doctor, Robert Koch, first identified TB in 1882 and reported 
success in isolating the causative agent of tuberculosis (4). The Zeihl-Neelsen strain, or AFB, 
was first described by two German doctors in the 19th century using a special bacteriological 
strain to identify Mycobacterium Tuberculosis (5). The diagnosis of TB using traditional 
methods, such as Acid Fact Bacilli (AFB), is still practised across the globe. Despite its 
suboptimum sensitivity (~50%), this diagnostic test continued to be used for decades as the main 
diagnostic test, especially in high burden countries, as it was often the only test available (6).  
Koch was the first to grow the culture of Tuberculosis in vitro and demonstrate that the disease 
was an infectious agent by re-introducing the bacterial culture to un-infected animals and 
infecting them with the disease (4). TB culture continued to be the gold standard test for 
Mycobacterium Tuberculosis until very recently. The main challenge with the TB culture is the 
complexity of the steps required and the biosafety requirements that are hard to achieve in low 
income countries. In addition, the delay in waiting time for results (which can take weeks) is one 
of the challenges in using TB culture for diagnosis. 
 
The rapid diagnosis of TB can help better control the disease and reduce the transmission of the 
agent. The use of rapid genetic identification of Mycobacterium Tuberculosis is an evolving 
technology that made the identification of cases much faster in addition to identifying the 
resistance in a one-step process. Many studies published in the period 2012-2013 showed the 
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positive value of GeneXpert/MTB test in the diagnosis of TB. Studies have reported that 
GeneXpert/MTB is a robust, simple-to-use test with high accuracy results in comparison to 
culture (10). 
 
The Visa Screening Service is one of the important elements of disease control in Abu Dhabi, 
United Arab Emirates. The upgrade of the service is a continuous process to ensure the best 
outcomes. The program was upgraded in 2008 by the adoption of the best available international 
guidelines in the diagnosis and early detection of priority infectious diseases, including HIV and 
TB. This included the adoption of an electronic system that captured all tests and results. It is 
integrated within a central unit of the Department of Health (DOH). The integration of the DOH 
and several screening centers was useful in providing comprehensive data for monitoring and 
evaluating the service. The DOH central team has issued detailed standards for visa screening 
services that defined the list of expected tests for any suspected cases and defined, in detail, the 
methods to be used for diagnosis, confirmation and reporting. AFB and culture were mandatory 
for all suspected cases with TB identified using Chest x-ray.  
 
The main objective of this study was to identify the links between evidence and practice for the 
implementation of  GeneXpert/MTB in tuberculosis screening settings. The study evaluates the 
performance of the GeneXpert/MTB test compared with culture pre- and post- implementation in 
visa screening centers in Abu Dhabi. A careful review of its accuracy was conducted in a pilot 
study to compare its sensitivity and specificity compared to culture and to define the algorithm of 







The study was conducted using two sources of data. The first dataset is a pilot study conducted in 
one central laboratory in the Disease Prevention and Screening Center (DPSC) in Abu Dhabi in 
2013. The data include 239 samples checked for three types of tests: (1) AFB smear  (2) TB 
culture, and (3) GeneXpert/MTB test. 
The second source of data is from visa screening centers: cases suspected of having TB during 
the period 2013-2014. This includes one year of data (2013) before the implementation of the 
GeneXpert/MTB test and one year (2015) after the implementation of the test in screening 
centers. The year 2014 was an overlap in the transition period during the implementation of the 
new screening system. 
 The data include all three regions of the Abu Dhabi Emirate: Abu Dhabi, Al Ain and Al Dhafra. 
This includes 11 visa screening centers. Samples were shipped to 3 central labs for diagnosis and 
confirmation. 
 
List of Variables Used 
The initial analysis was conducted on pilot study data using the following variables: Sample ID, 
AFB results, PCR: results of Xpert/MTB Test, and Culture: results of culture test. The second 





Data analysis was conducted using Excel and STATA software version 11.2 (Stata Corp, College 
Station, Texas, USA). Retrospective descriptive analysis was used to address sensitivity, 
specificity, PPV and NPV of each test. The calculation of confidence interval for each test was 
carried out to examine the significance of the findings.  The comparison of GeneXpert/MTB and 
culture was conducted for the total pilot sample (239 samples) and then calculated for subgroups 
(AFB smear positive and AFB smear negative). Figure 1 shows a summary of the pilot study 
samples used in the analysis. The second step of the analysis included a review of actual 
implementation data to examine changes in the detection of TB over time (pre-implementation 
and post-implementation). In addition, a review of the drug sensitivity data for the year 2015 was 
conducted for both tests. Logistic regression for TB confirmation over time was conducted to 




Figure 1 Summary of Samples Tested for smear microscopy, Culture, and MTB/RIF 
 
Exclusion and Inclusion Criteria 
Samples missing TB culture results (n=8) were excluded from the analysis. Results for TB 
culture reported as MOTT (n=13) or determined to be contaminated (n=10) were considered 
negative. 
For the Pilot Phase, all specimens tested were from sputum samples collected in the visa 
screening setting from suspected cases of TB. Samples included in the study were checked for 
sputum quality and were at least 5 ml. Samples were processed using the Zeihl-Neelsen method 
of acid Fast staining technique for microscopy. Processing for direct GeneXpert MTB/RIF 
(Cepheid, Sunnyvale, California) testing was performed according to the manufacturer’s 
instructions. Culture was conducted using Bactic MGIT 960 liquid culture. 
In the period prior to GeneXpert MTB/RIF implementation, all suspected cases for TB by chest 
X-ray were referred for sputum collection (3 samples were collected for each patient) and then 
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AFB smear microscopy and culture were performed. Figure 2 shows a summary of the TB 
detection algorithm prior to GeneXpert MTB/RIF. 
During 2014, a change in the algorithm was implemented to include GeneXpert/MTB/RIF in the 
testing (See Figure 3). 
 





Figure 3: summary of algorithm used for testing and confirmation of all suspected TB cases in visa 






The characteristics of the pilot study samples are shown in Table 1. Overall 249 samples were 
processed. The proportion of culture positive samples was 13% of the total samples tested. The 
proportion of GeneXpert/MTB positive was 9.2%. A total of 8 samples (3.3%) had missing 
culture results and were excluded from the analysis. Only 9 samples were found to be smear 
positive, and among those, 88.9% (8/9) were culture positive and 88.9% (8/9) were 
GeneXpert/MTB positive with identical results. 
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The majority of samples were smear negative (230 samples) and among those, 10% were culture 
positive (23 samples) and 6.1% were GeneXpert/MTB positive (14 samples).  
Table1: Summary of Samples used and tested for Smear, Culture and MTB/RIF 
 
 
The overall sensitivity of GeneXpert/MTB was found to be 51.6% (95% CI: 33.2-69.8). The 
specificity was 97.5% (CI: 94.5-99.1). The Positive Predictive Value (PPV_ was 76% (CI: 52.8-
91.8) and the Negative Predictive Value (NPV) was 93% (CI: 88.7-96.0).  The performance of 
the test for smear positives was very accurate with 100% Sensitivity, Specificity, PPV and NPV. 
However, the sample was small and the P value was not statistically significant.  
Whereas, for smear negative samples, the sensitivity of GeneXpert/MTB was 34.8% (CI: 16.4-
57.3). Specificity was 97.5% (CI: 94.3-99.1). PPV was 61.5% (CI: 31.5-86.1) and NPV was 93% 
(CI: 88.7-96). All comparative results of GeneXpert/MTB versus Culture are shown in Table 2. 
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Table2: Comparison of Xpert MTB/RIF and culture diagnostic test results in relation to smear 
microscopy (Pilot Phase) 
 
Section B 
Post Implementing GeneXpert MTB/RIF 
The summary of the annual TB detection rate for suspected samples who tested positive shows a 
statistically significant (P <0.001) increase from 2013 to 2015. This clearly shows improvement 
of overall detection of TB cases after the implementation of GeneXpert/MTB in 2015 in 
comparison to 2013. 
Figure 4 shows a summary of TB detection of the different tests over time. When observing 
detection using culture samples, it is clear that detection declines with time starting from 35.2% 
in 2013 to 21.44% in 2015 (P value<0.001). The year 2014 is the transition period when the 
detection methods were changing. In comparison to culture, GeneXpert/MTB detection increased 
over time: GeneXpert/MTB detection in 2014 was 19.5% whereas in 2015 it was 24.7% (P value 
was not statistically significant). 
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TB Antimicrobial Resistance 
The review of antimicrobial resistance data in 2015 after the implementation of GeneXpert/MTB 
is presented in Figure 5. Around 0.6% of samples tested with culture were found to be resistant 
and around 0.56% of samples tested with GeneXpert/MTB were found to be Rifampicin 
resistant. The benefit of early detection of GeneXpert/MTB for rifampicin resistance before the 
treatment enrollment was not captured in the data. The culture provided a more detailed 
resistance profile for first line medications, as are shown in Figure 5. Around 11 samples were 
found to have resistance to isoniazid using culture: the highest in comparison to other anti-TB 
medications (7 samples resistant to Streptomycin, 7 samples resistant to Pyrazinamide, 5 
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resistant to Rifampicin and 2 resistant to Ethambutol). 13 out of 16 samples were MDR 
compared to only 3 samples that showed single resistance to Pyrazinamide. 
 
Figure 5: Summary of MDR detected in 2015 by Culture and Xpert MTB/RIF 
 
DISCUSSION 
In the pilot study, the accuracy of GeneXpert/MTB was evaluated in comparison to culture and 
the accuracy of the results. The results of the study showed high specificity of the test in 
comparison to culture for the overall samples at 97% (95% CI: 94.3-99.1) and lower sensitivity 
51.6% (95% CI: 33.1-69.8), which is consistent with findings from others (8, 10, 12, 37). The 
test showed better performance in smear positive samples with identical findings in comparison 
to culture results with 100% sensitivity, specificity, PPV and NPV.  However, the sample of 
smear positives was very small and could not show statistical significance as there was very low 
statistical power. This finding is confirmed by other studies. A sensitivity of 98-100% of smear 
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positive samples was reported in a multi-centric study (12). Therefore, the use of 
GeneXpert/MTB in smear positive cases is equivalent to culture and can replace it.  
Several studies concluded that the rapid PCR method is a valuable, cost-effective and alternative 
tool for quick diagnosis of active tuberculosis in varying clinical specimens (9). One of the 
important values of GeneXpert/MTB is the reduced time interval for diagnosis and treatment in 
comparison with traditional methods of diagnosis. This will eventually lead to reduced patient 
defaulting during the investigation period and improve treatment coverage (6). The long-term 
impact of PCR in improving overall morbidity, more rapid treatment and the reduced 
tuberculosis transmission is under observation. In addition, the reduced amount of sample 
handling using simple techniques can certainly reduce the biohazard requirements for laboratory 
technicians and reduce the further use of culture in routine diagnostic settings (6). 
 
Based on these study findings, the TB testing algorithm was updated for visa screening medical 
testing and the new algorithm was adjusted for the differences in GeneXpert/MTB for both the 
sensitivity and specificity of the test. The low yield of negative GeneXpert/MTB can be 
improved by adding culture as a second step for the negative samples on GeneXpert/MTB to 
detect false negative cases. Using this order of testing will enable program managers to detect 
most positive cases earlier by GeneXpert/MTB. The minority of cases missed due to lower 
sensitivity can still be picked up by culture.  
The review of this study confirmed that the algorithm used in Visa Screening Centers after 2014 




The review of TB detection rates over time in Abu Dhabi showed improvement after the 
adoption of the new testing algorithm. This confirms the findings of other studies, where the 
Rapid PCR method using GeneXpert/MTB increased detection and treatment of multidrug-
resistant tuberculosis. It is now considered a valuable, cost-effective and alternative tool for 
quick diagnosis of active tuberculosis in different clinical specimens (9). 
 
This study did not cover the mean time for detection for both Culture and GeneXpert/MTB. This 
is covered in other studies and showed a major difference as the mean time for GeneXpert/MTB 
was 0 days (IQR 0-1), compared to 1 day (IQR 0-1) for AFB smear and 16 days (IQR 13-21) for 
liquid culture. This can be even longer for solid culture that takes around 30 days (IQR 23-43 
days) (12). 
 
Studies show that GeneXpert/MTB increases detection and treatment of multi-drug resistant 
tuberculosis (6). GeneXpert/MTB test sensitivity for rifampicin was reported to be 94.4% (236 
of 250) (12). Another study reported that MTB/RIF testing correctly identified 200 of 205 
patients (97.6%) with rifampin-resistant bacteria and 504 of 514 (98.1%) with rifampin-sensitive 
bacteria (37). The review of post-implementation results in 2015 in Abu Dhabi provided a 
positive value of early detection of rifampicin and more than half of those cases were detected by 
MTB/RIF. However, since the test does not detect other types of drug resistance, this could lead 
to some missed cases. 
 
This study did not address the cost impacts of the test in comparison to culture. This was covered 
by other studies that showed that GeneXpert/MDR can lower the overall cost of MDR cases that 
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required treatment due to the fact that the test will provide early results of resistance and can 
support physicians to provide the right drug combinations in the early stages and will have better 
outcomes (44). 
 
There are some challenges associated with the study. One was the small number of smear 
positive specimens that could not be changed due to the fact that the study was conducted on 
specimens collected in the past. Confirmation of the study finding was reassuring. However, if 
the smear positive samples had been higher, this could have strengthened the finding of test 
accuracy in smear positive samples. The study of post-implementation data included results after 
one year, which can be continued for subsequent years to measure the impact over a longer 
period. The results of detected pre- and post-implementation were assumed to be directly due to 
GeneXpert/MDR being implemented in 2014 (the transition period). The methodology of testing 
in the labs for visa screening centers was assumed to be similar because all of them followed the 
same standards of testing defined by DOH.  
CONCLUSION 
In our study, GeneXpert/MDR was found to increase TB detection after the implementation of 
the test in visa screening settings. The use of GeneXpert/MDR as a confirmatory test for 
suspected cases identified by chest x-ray has been previously reported by other studies to be 
effective and useful and this is confirmed by this study. In addition, the study provided some 
guiding algorithm for the use of GeneXpert/MDR, not fully replacing culture due to the 
limitations of the test (low sensitivity results in comparison to culture). The algorithm suggests 




APPENDIX 1 – List of variables used in Visa screening system 
Variable Name Label & Units Format Codes 
Year Year of test yyyy  
APP_NO Number of specific code for each 
applicant of visa screening. It is a 
unique number for each encounter 
with visa screening 




Nationality of visa screening 
applicants. Each country is 
mentioned 
Nationality list  
None 
 









Date of birth Date of birth of applicants Date: dd/mm/yyyy None 
Age Age in years number =INT(YEARFRAC(E3; 
K3)) 
VISA TYPE New or renew in the country text New or Renew 
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GENDER Male or Female text Male or female 
APPLICANT 
OCCUPATION 
Occupation of the applicant text List of occupations 
APPLICANT 
CATEGORY 





AFB SMEAR 1st AFB smear results first sample Text/number PH040 0 per 300 fields 
PH041 1 per 300 fields 




AFB SMEAR 2nd AFB smear results second sample Text/number PH040 0 per 300 fields 
PH041 1 per 300 fields 




AFB SMEAR 3rd AFB smear results third sample Text/number PH040 0 per 300 fields 
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PH041 1 per 300 fields 








TB CULTURE 2nd Culture results 2nd sample Text/number PH224 No growth 
PH228 MTB 
TB CULTURE 3rd Culture results 3rd  sample Text/number PH238 No growth 
PH239 MTB 
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CHAPTER 4  
Evaluation of TB Control Program in Abu Dhabi Using the WHO 




The health care system in UAE has undergone major structural changes in the last decade to 
improve the health care delivery system. The first change was in 2005, with the split of local 
health authorities from the federal Ministry of Department of Health Abu Dhabi (DOH), defined 
as the regulatory body for the Emirate of Abu Dhabi. It regulates the local health care system in 
coordination with the Federal Ministry of Health (MOH). DOH is also responsible for the design 
and implementation of all public health programs in Abu Dhabi. In addition, the introduction of 
the mandatory health insurance system for all residents in 2006 was the second milestone change 
that influenced the Tuberculosis Control Program. A new era of electronic surveillance systems 
for infectious diseases started around 2010 to strengthen the reporting and actions for infectious 
disease programs. TB was identified as one of the priorities of the infectious diseases program 
and the continuation of TB services in the health care facilities was one of the prime concerns. 
“The vision for DOH was defined to Ensure Reliable Excellence in Healthcare. The vision 
guided major reforms and the Department of Health Abu Dhabi (DOH) was created to regulate 
all healthcare sectors.”(1) Furthermore, Abu Dhabi Health Care Services (SEHA), the largest 
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public services provider, was created as the government body responsible for the delivery of 
health care services in the Emirate of Abu Dhabi.   
 
The regulation framework in the UAE is developing very rapidly to accommodate the rapid 
changes in the healthcare system and the level of economic development in the country. Some 
regulations issued and/or updated have had a major influence on the TB control program. These 
include Law no. (14) for the year 2014 concerning the control of infectious diseases, Ministerial 
Decree no. (7) for the year 2008 concerning medical testing for expatriates for residence or work, 
and Ministerial Decree no.(5) for the year 2016 concerning medical testing for expatriates for 
residence or work. In addition, local regulations for the Emirate of Abu Dhabi were important in  
encouraging updates in the TB control program. One of the local regulations that had a direct 
impact is: Law no. (23) for the year 2005 concerning health insurance in the Emirate of Abu 
Dhabi and the implementation of regulations. (4) 
 
The assurance of the best public health programs was a joint effort between the regulator and the 
provider. During this period, the tuberculosis control program in Abu Dhabi underwent major 
changes in adapting to the overall changes in the health care system. These changes included the  
automation of the reporting of TB, improved infection control measures within the healthcare 
facilities, and the introduction of the TB DOT program in primary health care facilities. Prior to 
2010, all care provided to TB patients was limited to secondary care hospitals and the private 




The Global Strategy for the TB Control program defined by WHO was also evolving and 
undergoing revisions and updates to promote health in the target countries to control the disease 
better. In 2006, WHO developed the Stop TB Strategy. Targets and goals were set and among 
them was the Millennium Development Goal 6: “ The strategy aimed at ensuring TB burden 
falling by 2015 that prevalence and mortality rates are halved by 2015 compared with a baseline 
of 1990.”(2).  
The Stop TB Strategy had six major components: 
1. Pursue high-quality DOTS expansion and enhancement 
2. Address TB/HIV, MDR-TB, and the needs of poor and vulnerable populations 
3. Contribute to health system strengthening based on primary healthcare 
4. Engage all care providers 
5. Empower people with TB and communities through partnership 
6. Enable and promote research 
This strategy was further revised in 2014 and updated in the 2015 Global TB Strategy. The 
strategy aims to end the global TB epidemic with targets to reduce TB deaths by 95%, to cut new 
cases by 90% between 2015 and 2035, and to ensure that no family is burdened with catastrophic 
expenses due to TB. It sets interim milestones for 2020, 2025, and 2030.  
The strategy creates a roadmap for governments to adapt and implement with high-level 
commitment and financing as follows: 
 “It reinforces a focus within the strategy on serving populations highly 
vulnerable to infection and poor health care access, such as migrants. The 
strategy and resolution highlight the need to engage partners within the health 
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sector and beyond, such as in the fields of social protection, labor, 
immigration and justice. The resolution requests the WHO Secretariat to help 
Member States adapt and operationalize the strategy, noting the importance of 
tackling the problem of multidrug-resistant TB and promoting collaboration 
across international borders. WHO also recommended monitoring the 
implementation and evaluating progress towards the milestones and the 2035 
targets” (5) 
The rapid development of TB diagnostics also occurred in the same period and more accurate 
and faster diagnostic tests such as GenXpert and other rapid molecular tests were gradually 
developed and used to provide information about disease activity. Those tests saved a lot of 
waiting time (between 4-6 weeks waiting for culture results) and now results are available within 
days in most cases. 
With all of those changes locally and globally, it is important to have a clear understanding of the 
Tuberculosis Control Program in Abu Dhabi so as to understand the changes in the program and 
devise recommendations on how to improve program performance and achieve targets set by the 
WHO strategy to End TB. The evaluation is a prospective, qualitative review. It uses semi-
structured interviews conducted during 2017 to gain a better understanding of the program at 
various levels of the health care system including primary care, secondary care, diagnosis, 
management and monitoring at local levels. The main objectives of the evaluation were: 




• To provide policy makers with a clear overview of program performance and suggest 
improvements to current practice 
• To provide guidance for strategic planning for TB control 
• To strengthen the collaboration between key stakeholders in the health care system that 
have direct impact on the TB program 
• To identify challenges in meeting the objectives of the national TB program 
• To assess whether progress has been made towards achieving national, regional and 
global targets 
• To assess the performance of the programme in delivering strategic interventions, assess 




Forming the working group 
 
The study is prospective using qualitative, semi-structured interviews and utilizing WHO 
existing tools to evaluate program elements in various health care settings. These include 
screening, diagnostic and management facilities in addition to the central program unit in Abu 
Dhabi. To ensure a reliable evaluation process, a team of evaluators was formed from the 
following stakeholders: 
1- Academic institution expert specialized in public health (1 member) 
2- Ministry of Health program leads of TB (3 members) 
3- Private hospital consultants on pulmonology or infection control (3 members) 
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4- Public Hospital consultants in infectious diseases or infection control (5 members) 
5- Health Authority Abu Dhabi TB program leads or audit team (4 members) 
6- Visa Screening Centers (3 members) 
7- Laboratory experts in microbiology (1 member) 
The first meeting included a comprehensive review of program components and evaluation 
objectives. The group divided into subgroups to review the WHO checklist and revise the 
contents of the questions to be used in field evaluation.  
The second meeting included review of expected deliverables and finalization of the checklist. 
Content not applicable to the local healthcare system was removed. This included assessing the 
implementation of the practical approach to lung health (PAL) which is not implemented in the 
health care system but rather focusses on the DOT program. Some questions were added to 
check the awareness of health care providers about DOH DOT standards. 
Before conducting the field visits, all evaluators were trained in standardizing the process and 
conducting the questionnaire. 
Various questionnaires were used based on the type of service provided. For example, screening 
facilities played a major role in active case-finding and diagnosis and referral, but not in 
management stage. Questions related to patient management from those facilities were excluded.  
The field visits were arranged to observe the infrastructure and functions of each organization 
based on the checklist provided. The evaluators were divided into groups of two and assigned to 
visit facilities. This exercise was helpful for stakeholders to identify the roles of other 
stakeholders and challenges arising in various settings. 
The following areas were covered in the evaluation: 
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1. Management of the national TB program 
2. Local strategic plan for TB prevention, care and control   
3. TB case-finding   
4. Quality-assured diagnoses made by TB laboratories 
5. Quality of TB diagnoses 
6. Management of TB cases  
7. Programmatic management of drug-resistant TB   
8. TB/HIV collaborative activities  
9. Patient adherence to TB care  
10. Management of anti-TB medicines and supplies  
11. Recording and reporting  
12. Activities to address childhood TB  
13. Assessing infection control practices related to TB in the facilities 
14. Public–public and public–private mix approaches  
15. Engagement of civil society, non-governmental and community organizations 






Figure 1: Summary of the Review stages and timeline 
 




The study was conducted over a one-year period starting with an overview of existing 
international models of evaluation for TB control program elements and a comprehensive 
literature review. The WHO framework of evaluation was selected as the main reference for 
evaluation. Checklists suggested by WHO were revised to ensure consistency and applicability 
to the system. The second phase included selection of the evaluation team. Selection was based 
on expertise in the area of infection control, laboratory, infectious disease consultants, 
pulmonary consultants, epidemiology or health audit experience. The group was drawn from the 
private and public sectors from local and national levels. It was considered that a group mix 




The evaluation covered all three regions of Abu Dhabi Emirate: Abu Dhabi (Central region), Al 
Ain (Eastern region), and Al Dhafra (Western region). This was intended to ensure a 
comprehensive picture of the program given that each area has different settings, requirements 
and expectations. The selection of major health care providers in each region sought to represent 




All checklists completed by the evaluators were collected and entered in Excel and used for the 
analysis. The main program used for the evaluation was Excel. Data quality was evaluated by 
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assessing completeness and accuracy of information. Each checklist was filled and reviewed by 
two evaluators who visited the facility to ensure accuracy of information captured. 
 Facilities were grouped by region and roles within the health care system. Two distinct 
checklists were used in the interviews: 
A- Local regulatory level:  
Evaluation of TB control program planning, surveillance and monitoring in Health 
Authority Abu Dhabi 
B- Public and private diagnostic facilities:  
Evaluation of performance against expected roles in various stages of patient 
management pathways including case detection, management and isolation, diagnosis, 
and follow-up. Further grouping and analysis were conducted separately for screening 
facilities because their role was different from other diagnostic facilities and the 
expectations were different. 
 
Analysis of Checklists 
 
The facilities questionnaire included 218 questions grouped according to the stage of patient 
care. Some questions were skipped during interviews if not applicable for the facility according 
to their roles. For example, in visa screening facilities there is no in-patient management because 




Stages of the Study 
 
Analysis of visa screening results began with assessments of trends over time, frequency 
distributions, and tabulations. A summary of new and renewal results was given and included 
positive culture, PCR, and smear results. In addition, an analysis and calculation of mean and 
median values for different variables was carried out. The review of visa screening applicants 
was based on residency status (new applicants versus renewals) based on previous research that 
confirmed substantial differences in TB rates between both types. 
 
Scope of Evaluation 
 
The analysis was first conducted for each dataset separately (pulmonary TB notifications and  
extra-pulmonary notifications). Data quality was reviewed and included the completeness of 
fields and the selection of fields useful in the analysis. Frequencies and distributions of age 
groups and nationalities were calculated. It is important to highlight that this method of passive 
reporting from hospitals included additional clinical details such as risk factors, drug resistance 
and previous history of the disease. Although not all fields were fully completed, most cases had 




The questionnaire was a very help tool to structure the visits and to review all the elements of the 
TB control program. The revised checklists are included in Appendices 1 and 2. All completed 
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forms have been collected and analyzed, then followed by a discussion with the evaluation 
group. The following sections are a summary the main findings. 
Section A 
Local Regulatory Level of TB Control Program  
The central level of the program is the heart of the whole system and it is a critical component of 
the evaluation. This section was evaluated by experts in TB epidemiology for the National 
Program and an academic partner. The TB control program follows the National TB strategy in 
the UAE. There are clear national regulations for TB control defining requirements of reporting 
at the local level. There are also clear standards defining the role and responsibilities of each 
organization within the health care system at local level. The national and local policies exclude 
defined targets of reduction in the next 5 or 10 years, in line with WHO global targets. There is 
no national or local policy on HIV/TB collaborative activities and this is one of the areas that 
requires improvement. The local standards define the requirements for diagnosis, reporting and 
case-management of patients with TB produced by the Communicable Diseases Department 
(CDD). One of the gaps identified, treatment for children, was not clearly defined in terms of 
patient management and prophylactic management. The focus was exclusively on adult patients. 
Some case definitions in the standards should be updated based on current WHO case 
definitions. 
Reporting from Local to National level is done on a regular basis based on a set of templates 
defined by the national program coordinator monitoring the situation. Figure 2 shows the 
conceptual framework for TB control program elements and includes some of the KPI measures 
to monitor program performance. 
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The program also defined the funding for TB management for patients excluded from the 
national insurance scheme. The team conducts multiple training activities for health care workers 
and coordinates supervisory visits to follow program implementation. One of the areas of 
improvement is to include training materials for TB management in children. In addition, the 
staff in the central unit can be trained on how to conduct supervisory visits to ensure consistency. 
After each supervisory visit, a summary report is prepared for the management indicating 
strengths, weaknesses and recommendations.  
One of the program strengths is the electronic reporting system that captures all of the cases from 
suspicion to final outcome of management. This comprehensive database is not available in other 
entities in the country and can be shared with other local or national entities. The electronic 
program is a very helpful tool to identify the actual performance of each facility. The analysis of 
the data is automatically generated to provide the program lead real-time information and 
captures the program KPIs. Table 2 shows how KPIs are monitored on a regular basis and used 
in setting useful local targets to guide future evaluation of program performance. 
The human resources capacity seemed to be an issue in the central level due to the limited 
number of staff to follow up the TB contact tracing process and patient adherence to regular 
follow-ups in TB DOT clinics. 
The feedback about TB cases reporting is shared with stakeholders by quarterly summary reports 
as part of the Communicable Diseases Bulletin. A collaboration among various stakeholders 
within the TB control program seems to exist within the healthcare setting. Very limited 
information, however, is available about collaboration with other stakeholders outside the 
healthcare system. This area can be strengthened in the future in terms of TB awareness activities 
or the funding of TB control program activities.  
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The activities related to TB research are limited to academic institutions. There is no link with 
the local health department to ensure that research priorities are met.  
There is no awareness plan for TB to address knowledge gaps or stigma that might be related to 
the disease. The engagement of patients, communities or civil society organizations was not in 
the plan. The main highlighted issue was lack of budget for TB activities and awareness. There 
are very limited efforts to link with other sectors that may be affected by TB such as labor or 
social services. There is good link of awareness and shared activities established with 
immigration and social policy services. 
Figure2: Conceptual framework for TB control program.
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Table 1: summary of KPIs for TB control program in Abu Dhabi. 
Contact Tracing Process 
 
This is a shared activity among the local regulatory authority, screening centers and other health 
care facilities. It is an important step in TB control. Figure 3 outlines TB contact tracing in Abu 
Dhabi. Based on the questionnaire, approximately 63% of facilities provide contact-tracing 
services for people exposed to TB. The private sector seemed to be not included in this process. 
In addition, more than one tool is used to assess closed contacts, including chest x-ray in 80% of 
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facilities. In addition, TST and IGRA are both used to evaluate contacts in 70% of the facilities. 
Sputum smear and clinical assessment also used for evaluation. 
 
The categories of contacts included in chemoprophylaxis treatment included elderly, 
immunocompromised, children below 5 years of age and contacts with latent TB. 
Chemoprophylaxis for children is limited to secondary care hospitals and the access is very 
difficult for all contacts. This is one of the gaps to be improved.  
 





Visa Screening Centers  
The epidemiology of TB in Abu Dhabi described in the previous chapter defined case detection 
of expatriates as one of the program priorities due to the high proportion of expatriates compared 
to that of the local population (nationals) especially since most come from countries with a high 
burden of TB. Most TB cases diagnosed every year are detected from visa screening centers. 
There are detailed standards at the local level that define the expected screening requirement and 
details of diagnosis and confirmation required for every suspected case. 
There is consistency in terms of diagnosis methods across the centers in alignment with local 
standards. There are central labs for referral of samples for confirmation that have the capacity to 
conduct smear testing, using GeneXpert and culture. In terms of drug sensitivity, only rifampicin 
resistance is conducted as part of GeneXpert test for smear positive cases, which is acceptable 
for screening facilities. For smear negative cases, culture is done to rule out TB and no drug 
sensitivity testing is done for those cases. Table 2 notes the performance of visa screening 
centers for each level of TB patient pathway. The evaluators commented on the high standard of 
labs available at the central level. In addition, induction negative pressure rooms were observed 
with high standards and clear monitoring. A nurse was routinely available. Staff are aware of 
infection control measures for TB and good practice was noted during the visits. One evaluator 
commented on a men’s changing room for X-ray: it was a confined space allowing close 
exposure to other people and could increase the risk of TB transmission from symptomatic cases.  
One visa screening center provides TB DOT treatment services in addition to case detection. 
Concerning training, staff in two out of the three facilities visited confirmed recent awareness 
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sessions of TB management and control. Training for staff in those centers is very important to 
ensure adherence to infection control measures and the continuous development and update of 
knowledge about TB case detection and management.  
 








Primary and Secondary Health Care Facilities  
A total of 11 health care facilities in the review included 5 public secondary care hospitals, 5 
private hospitals and 1 primary health care center, as shown in figure 4. These facilities were 
distributed in the following regions: 
8 facilities in Abu Dhabi 
2 facilities in Al Ain 
1 facility in the western region. 
 
Case Finding 
Case finding is usually done based on clinical presentation and x-ray findings in all facilities and 
the suspicion of a case with cough for more than two weeks in absence of other causes. Local 
standards define the required set of tests for a diagnosis of TB including sputum smear, culture 
and GeneXpert test and there seems to be good access to those tests across the system. Private 
hospitals refer culture samples for confirmation in public, designated labs due to the absence of 
this facility in the private sector. All health care facilities seem to be aware of the reporting 
requirement to the local regulatory authority. Around 73% of facilities routinely evaluate TB 
among HIV positive patients. 
Suspicion of TB in patients who have had a cough for more than two weeks is done in 60% of 
the facilities. In addition to clinical suspicion, 75% of the facilities reported using radiological 
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findings in CXR and, to a lesser extent, CT is used by approximately 60%. Further, around 60% 
of the facilities request culture for the diagnosis of TB. 
A diagnosis of extra-pulmonary TB is mainly done using clinical presentation in 88% of the 
facilities. Taking a biopsy for histopathology is also done in 88% of the facilities. Around 78% 
of facilities send the sample for AFB smear and culture. 
The facilities are aware of the reporting requirements to the DOT TB central unit using the 
electronic notification system. All interviewed personnel have a valid account in the notification 
system and are aware of reporting requirements at different facility levels. 50% of interviewed 
facilities said that the reporting of TB was easy while 50% said it was moderately easy to do. 
Sputum Collection 
The collection of sputum samples is a very important technique that needs to be well defined due 
to the risk of TB transmission during the collection procedure. Evaluators commented that most 
health care facilities have a designated space for sputum collection: either a negative pressure 
room or a location outside the building. One major finding concerning sputum collection in 
primary health care centers is that a designated space is generally not identified: patients were 
normally asked to use public toilets for the collection of sputum. This poses a real risk to other 
patients and needs to be brought to clinic management attention. The observation of the sputum 
collection is done by various health care professionals such as doctors, nurses or lab technicians 
in various settings. The provision of detailed guidance of the requirements for rooms for sputum 
collections together with the provision appropriate educational material might be helpful to 




Case Management and TB Medication: 
It is clear from the evaluation that the treatment of TB is limited to public hospitals. Referral is 
usually initiated by private hospitals. Evaluators highlighted the issues of patient bed availability 
in public hospitals and the non-availability of medication in the private sector. The availability of 
anti-TB medicine in the private sector is not clearly defined although the general understanding 
is that treatment is limited to public hospitals.  
There is a noticeable gap in referrals for treatment from private to public hospitals due to the lack 
of bed availability in public hospitals. If a patient in the private sector is suspected of having TB, 
samples can be taken and sent for further diagnosis and confirmation. Patients are usually not 
admitted and there is no access to medication, even if active TB is suspected and the patient 
shows symptoms. Private hospitals reported difficulty in referring patients for admission to 
public hospitals.  
Around 55% of facilities conduct drug sensitivity testing for confirmed TB cases and around 
75% had a system to follow up results. 
Health care professionals reported a good knowledge of DOH standards for TB management. In 
addition, some facilities developed their own guidelines or use the international guidelines 
published by CDC or WHO. 
Around 60% of facilities call patients if they fail to come for collection of medication and follow 
up of defaulters is also done by the Central Department in DOH. 
Possible reasons behind lack of patient compliance regarding TB medication was discussed. 
Professionals indicated that patients often discontinue treatment due adverse effects related to 
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medication. Other reasons are transportation issues, problems at work and the delivery of 
medicine.  
It is noticed that all first lines are available in all facilities providing TB treatment and there is no 
issue regarding supply. However, only 50% of facilities have second-line medication available. 
In facilities which provide HIV treatment, it is clear that there is integration of management and 
prevention of TB. Patients with HIV are offered preventative Isoniazid therapy. They are 
routinely screened for TB at initiation of HIV treatment and also if they develop suspicious 
symptoms indicative of HIV. 
Treatment of TB is partially covered by insurance and there is a co-payment required that is 
covered by the patient directly or by their sponsor. This is one of the issues for patients with low 
incomes such as ordinary workers, especially if they have MDR or XDR: the cost is high for 
such cases and cannot be afforded by some patients. 
Around 55% of facilities reported that TB patients indicated that their families believed that TB 
could be cured. Some patients reported that TB was life-changing (15%) and that they suffered 
from stigma related to the disease (30%). Around 40% of facilities reported that patients feel 
stigmatized because of their disease. 
 
TB in Children 
The evaluation identified a major gap in service for preventative treatment in children. Most 
facilities are not aware that preventative therapy for TB is required for children under 5 years of 
age when exposed to a TB patient. There is a lack of counseling and educational services on 
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offer for children and their families to convince them about compliance of treatment. A diagnosis 
of TB in children is difficult and needs a lot of awareness and knowledge especially in primary 
health care settings. It is even more difficult to ensure the compliance of children for six to nine 
months of treatment. The lack of designated services with good access is one of the issues 
identified during evaluation. National and local guidelines only covered adults and did not 
elaborate about diagnosis, treatment or prevention of TB in children. Two tertiary care hospitals 
provide the treatment for TB in children with very difficult access, especially for expatriates. 
 
Laboratory Capacity for TB Diagnosis 
There are three main designated labs for TB confirmation. They have trained personnel to 
conduct TB smear, culture, and GeneXpert and baseline sensitivity testing. MDR sensitivity 
testing is available although no labs had full panel for testing XDR. This is an issue especially if 
the patient is not responsive to treatment and a change of medication is based on laboratory 
testing for second line medication. In some individual cases, samples are sent abroad for testing. 
Access to TB culture in the private sector is done through referral of samples to designated labs 
in the region and is similarly done for all suspected cases.  
 
Infection Control Practices related to TB 
The evaluation highlighted some of the strengths related to infection control practices such as the 
isolation of patients suspected of or confirmed with TB in a negative pressure room or separate 
rooms. The surveillance of TB among health care workers is established routinely in 65% of 
facilities evaluated. A practice breaching infection control noted in the reports was the use of 
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public toilets in one of the facilities for sputum collection. However, the majority of facilities had 
a designated area for sputum collection with negative pressure or hepa filter. The introduction of 
sputum facilities in visa screening centers was highlighted by evaluators as a model for good 
infection-control practice. 
 










This is the first comprehensive review of the program conducted at local level in Abu Dhabi. 
This review could be useful in supporting the program’s development and improvement. This 
evaluation was conducted by various members of an evaluation working group using the 
checklists in Appendices 1 and 2 together with field visits to major health care facilities 
including both private and public providers. This evaluation could be a baseline for future 
evaluations to measure any change and performance in the TB control program. The UAE is 
included in the list of low burden countries based on the WHO Global Report, 2016. The UAE 
had a total burden of TB 1.6 per 100,000 population in 2015, a burden of HIV <0.1 per 100,000 
population, and very low burden of MDR (0.17 per 100,000 population) (6). This report includes 
the most updated figures and is descriptive of TB epidemiology in the local population. Figures 
exclude the expatriate population and immigrants living in UAE who comprise around 80% of 
the total population. Most expatriates come from the top ten countries with a burden of TB such 
as India, Pakistan, Philippines, Indonesia, and China (6). The first paper provided a detailed 
report about the epidemiology of TB in the UAE capital, Abu Dhabi, and provided details about 
the high-risk group population. Most of the evaluations published focused on the reporting 
system and the quality of data (23). Another evaluation of the TB program in India focused on 
patient compliance to TB DOT treatment. It found that older, male patients tended to default 
from TB treatment and the study discussed barriers to TB Treatment (18, 27, 29). Various 
elements of TB control program were covered based on WHO requirements of a TB control 
program. 
The WHO End TB Strategy aims to end the global TB epidemic, with targets to reduce TB 
deaths by 95% and to cut new cases by 90% between 2015 and 2035, and to ensure that no 
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family is burdened with catastrophic expenses due to TB. It sets interim milestones for 2020, 
2025, and 2030” (7). In the following sections, WHO strategy principles and the main pillars in 
the local perspective will be reviewed to compare the strengths and weaknesses in various 
elements of the TB control program. This will provide policymakers with a view of program 
performance and provide insights into opportunities for improvement. 
 
The Main Principles of WHO Strategy 
1. Government stewardship and accountability, with monitoring and evaluation 
The control program focused on the establishment of a strong surveillance system by electronic 
reporting covering all different stages of the disease until recovery: a useful tool for continuous 
monitoring of the disease. Throughout the review, it was noticed that a strong collaboration 
existed between health care providers and the DOH central team,  and that there was cooperation 
with limited stakeholders such as social services. The monitoring of TB management outcomes 
is a very crucial element of program success. There are some barriers for patients to complete the 
treatment course such as inadequate level of awareness about the disease, complications of 
medication, and difficulties accessing the TB DOT service. Some new effective ways of 
monitoring TB medication compliance uses mobile applications and video recording of patients 
that can sometimes replace the need for physical visits to clinics.  
2. Strong coalition with civil society organizations and communities 
The collaboration with external stakeholders can be further strengthened by mapping all 
organizations that may be impacted by the disease or have a shared interest. Based on the 
mapping of key stakeholders, the team can further initiate communication to strengthen the 
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relationship and get support in areas that require coalitions. An example of possible partners will 
be major employers in the private sector or non-profit organizations. The coordination with HIV 
programs and stakeholders is another area that can be emphasized and strengthened. 
3. Protection and promotion of human rights, ethics and equity 
It is clear from the review that access to health care services in public hospitals is provided to all 
patients. The insurance system provides partial coverage for TB treatment and the government 
provides coverage for patients who do not have insurance coverage. The next step recommended 
is a revision for patients who have a co-payment and have limited income to cover additional 
costs. It is very important to cover low-income patients as they are a high-risk group and because 
this might lead to an increase in defaulters and the risk of further TB in the community. It is 
important to revise access details by mapping patients and services to make sure that DOT 
services are provided in areas with high numbers of TB cases. Some gap areas identified during 
the evaluation is workers’ camps where there is no local public clinic available. A possible 
solution for this issue is to revise the private services provided locally and to contract them to 
provide TB DOT treatment. It is clear that the management of TB is currently limited to public 
providers. This could be adequate if they have the capacity to take all patients to ensure access. It 
is clear, however, that the public health sector has a limited capacity and resources and will be 
required. Support from the private sector will also be required especially in areas where there is 
no public service provision. It is important to provide TB medication to private hospitals and 
train staff on the handling and management of TB cases. It is important to monitor the 
percentage of TB defaulters and have a detailed analysis and to study the reasons behind any 
discontinuation  of medication. 
4. Adaptation of the strategy and targets at country level, with global collaboration  
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It is important to develop a continual revision program in line with the WHO End TB Control  
Strategy and its regular updates. The review done in Abu Dhabi covers a local program and it is  
important to conduct a similar exercise at national level. 
 
 
WHO End TB Strategy Main Pillars  
1. Integrated, patient-centered care and prevention 
It is clear from the review that the early diagnosis of TB has been encouraged in both public and 
private facilities with a clear role and responsibility matrix in the TB DOT standard of care. Most 
facilities are aware of case definitions and how to suspect and report TB. In addition, most staff 
received training about the TB program. A study conducted in Oman noted that there is 
inadequate knowledge of TB among GPs in the private sector compared to GPs in the public 
sector (9). The procedure for the diagnosis of TB is very well established and there is a clear 
pathway for referrals of samples for confirmation. There is a clearly identified mechanism for 
referral of samples from the private to the public sector. The inclusion of the private sector in the 
management of TB needs to be done to improve access in areas not served by public hospitals. 
There is a clear gap in drug-susceptibility testing for second line medication that needs to be 
revised to ensure that there is at least one lab capable of conducting second line sensitivity 
testing.  
The TB screening program is widely used. It covers high-risk groups and provides data about 
active and latent tuberculosis. Positive cases are referred for treatment and admission. In 
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addition, contact tracing is conducted among those at risk of infection who require prophylactic 
medication. There are two gaps identified that can improve the outcome and have a huge impact 
in the overall rate of TB. First, prophylactic treatment is currently not provided for all latent TB 
cases identified at first screening. Second, provide access to preventative services for children. 
This currently provided by selected secondary care hospitals with very limited access and 
capacity. 
The treatment of all patients with TB is covered by the national insurance program. The UAE 
government provides for patients with no insurance coverage. There is, however, a co-payment 
associated with TB treatment for some patients: those with drug-resistant TB and those requiring 
patient support.  
A study conducted in India found that the main reasons for poor adherence to TB medication 
were poor knowledge about TB, forgetfulness, and the lack of outreach and educational 
programs for TB (33). A review conducted to understand barriers to TB management adherence 
in immigrant and high-risk populations listed the main barriers to be fear, anxiety, denial and 
stigma. In addition, the use of incentives was suggested as the best intervention to improve 
access to care and compliance (34). The reason behind the lack of patient compliance reported in 
this evaluation is adverse effects related to medication. The main reason for defaulting in 
treatment is transportation issues. Other barriers reported were problems at work, delivery of 
medicine, and stigma of the disease. Some suggested interventions are improvement in access for 
TB management, the provision of awareness programs for TB, and the discussion of  possible 
incentives for the treatment of high risk groups. 
2. Bold policies and supportive systems 
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A TB control program is one of the health priority areas at both national and local level. Most 
efforts are currently focused on screening and early detection. There is engagement with health 
care providers in the public and private sectors. Engagement with other stakeholders beyond the 
health care system is crucial and can be improved upon as they can actively participate in TB 
awareness and support programs. 
 
3. Intensified research and innovation 
Research into TB is very limited in the Gulf region. This could be the case due to the low level 
and support of research in the medical field in general, both regionally and locally. Regional data 
available to this study were very limited. Local research is required into regional TB incidence to 
gain a better understanding of the issue and to optimize the implementation and impact of a 
control program. The development of new strategies and tools for an effective TB control 















TB Evaluation Framework for health care facilities 
 
Name of facility:   
Date of the visit:      /  5  / 2017 
Time: from               To    
 
Visiting team: 
 Name Place of work Mobile No. signature 
1     
2     
3     
4     
Staff from the facility interviewed: 
 Name Place of work Mobile No. signature 
1     
2     
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3     
4     
5     
6     
Report submitted to CDD/HAAD on      /       /2017 
 













Part (1) Assessing TB Case-finding 
Location: specialized and non-specialized outpatient clinics at health facilities 
Staff to be met: Health-care workers (such as doctors, nurses, medical assistants and clinical 
officers) 
A. Identifying people suspected to have TB 
 
1. How do you identify a suspected TB case? MCQ 
a. Clinically  
b. radiologically   
c. laboratory  
d. others _________________ 
 
2. What are the clinical criteria for suspecting TB (for example, do you ask patients if their 
cough has lasted for longer than 2 weeks)?  
a. Yes  
b. No 
3. Mention the other clinical  criteria for suspecting TB 
__________________________________________________________________
__________________________________________________________    
4. Do you evaluate patients who are HIV-positive? 
a. Yes  
b. No 
5. Have the physicians and other health-care workers been trained to identify and manage 
people suspected of having TB, including those suspected of having drug-resistant TB?  
a. Yes   
b. No  (Go to Section B) 
c. I don’t know (Go to Section B) 
6. When was the training provided? 
Date (dd/mm/yyyy) _______________________ 
7. Who provided it?  (Trainer’s organization ) MCQ 
a. HAAD 
b. SEHA 
c. Same facility,  
d. Other entity (mention): _______________________________ 
 
B. Managing people suspected to have TB 
8. Do the health-care workers follow the available algorithms (DOT – DOH standard 
including the clinical care pathway) or standard operating procedures when assessing 
patients? (Check and verify facility documentation like patient medical  records) 
a. Yes  
b. No 




a. Testing with sputum microscopy,  yes  No 
b. chest radiography       yes  No 
c. Xpert MTB/RIF (PCR) test   Yes  No 
10. Do the health-care workers use a combination of screening tools (radiological and lab. 
investigations) and assessment procedures (history and clinical signs and symptoms)?  
a. Yes  
b. No 
C. Managing Sputum: 
11. What is the procedure for sputum collection? MCQ 
a. Expectoration mechanism  
b. Induction 
c. Others e.g.  Gastric aspiration, bronchoscopy, (Mention please) _____________ 
12. Where is sputum collected?  
a. Negative pressure room in the lab 
b. Isolation room in the ward or ER  
c. Negative pressure room in the ward or ER 
d. Others (mention please):_____________________ 
13. Observe whether sputum is collected in: 
a. Well ventilated areas or  
b. Outside the building. 
c. NA (No sputum collected during the time of visit) 
14. Are the infection control precautions taken during sputum collection? (Check and verify ) 
a. Yes 
b. No 
15. Are the sputum-collection containers adequate (never experienced stock out)?  
a. Yes 
b. No 
16. Are they labeled properly (Name and MRN of patient, date of collection)? Recommended to 
check collected sputum sample if possible. 
a. Yes  
b. No 
 
17. Is sample processing lab services available (is sputum sample examination for TB disease is 
available at the facility lab)? 
a. Yes (skip the next question) 
b. No  
18. If the samples are not processed in the same facility, how often are specimens transported?  
 daily  
 weekly 
 others:______________________________ 
19. Who is usually responsible for instructing the patients how to produce sputum?  
a. Clinic physician 
b. Clinic nurse 
c. Lab technicians 
d. Others:________________________________ 
D. Managing drug-resistant TB 
20. Is there a system for following up patients suspected of having drug-resistant TB?  




c. I don’t know 
21. Is there a register where patients referred for drug-susceptibility testing (DST) are recorded? 
a. Yes  
b.  No 
c. Others, mention please _________________________________________ 
E. Managing X-ray: 
22. Is chest radiography available? 
a. Yes (answer next question) 
b. No (skip next question) 
        23. Is chest radiography used?  
a. Yes 
b. No 
       24.  Are people suspected of having TB referred elsewhere for chest radiography?  
a. Yes (answer next question) 
b. No (skip next section) 
25. How does the referral procedure work? (Recommended to ask the transfer nurse if available) 
a. easy   
b. moderate   
c. difficult to handle 






F. TB contact investigation 
 
1.  Are the procedures for screening and assessing TB contacts clearly defined?  
a. Yes  
b. No 
c. I don’t know 
 
2.  Are algorithms available for health-workers to use?  
a. Yes   
b. No 
3. Have staff who should carry out contact investigations been identified and are their roles well 
defined?  
a. Yes   
b. No 
4. Is there an information system (or register) that can be used to monitor and evaluate contact-
investigation activities?  
a. Yes   
b. No 
5. What is the initial assessment tool of contacts? MCQ 
a. clinical 
b. TST (Tuberculin Skin Test)  
c. IGRA (Interferon Gama Release Assay) 
d. X-ray  
e. Sputum bacteriology  
f. Others (mention please) ______________________ 
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6. Is chemoprophylaxis or treatment for LTBI (Latent TB infection) provided to TB contacts?  
a. Yes 
b. No 
7. If yes, to which categories of contacts is chemoprophylaxis or treatment for LTBI provided? 
MCQ 
a. Children less than 5 years 
b. elderly  
c. immunocompromised 
d. LTBI 
e. Others_________________  
8. What medicine of chemoprophylaxis is provided to contacts? MCQ 
a. INH  
b. Rifampicin   
c. Others_______________________ 
9. Are there any follow up steps for those contacts enrolled in chemoprophylaxis? (e.g. there is a 
register or excel sheet or any form of follow up to follow their compliance with the treatment 
schedule) 







Part (2) Assessing quality-assured diagnoses made by TB laboratories 
Location:   intermediate laboratory or Health care facility laboratory 
Staff to be interviewed: laboratory manager or director, laboratory technicians 
 




2. How would this lab classified? 
a. Primary healthcare lab. 
b. Secondary healthcare lab 
c. Tertiary healthcare lab. 
d. Reference lab 
3. What is the laboratory’s catchment area? MCQ 
a. Abu Dhabi island and middle region 
b. Al Ain region 
c. Al Dhafra / Western region 
d. Others (mention please) _______________ 
4. What is the general population size served by this lab? Estimated if available:                         
( _______________________________________________)  
5. How many other (public & private) laboratories are there (for this catchment population) 
in the catchment area served by this lab. (_______________) 
6. How many technicians work in the laboratory? (_________________) 
7. How many staff are qualified/ experienced in sputum microscopy? ( _______) 
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8. How many sputum specimens are processed? if the samples are not processed at the same 
facility lab please mention zero (verify) 
a. Daily (_______________) 
b. weekly  (_______________) 
c. monthly (_______________) 
9. Has laboratory staff followed safety measures for laboratory works? observe and verify 
a. Yes 
b. No 




11. Are the smears prepared and stained, and reagents stored, in an appropriate area? Check 
and verify (observational) 
a. Yes 
b. No 
c. Not applicable 
12. Does the laboratory receive sputum specimens from an outpatient clinic or other facility? 
a. Yes 
b. No   Go to question 14 
13. If yes,  
a. How is the specimen delivered to the laboratory?  
______________________________________________________  
 
b. How is the specimen stored before being sent to the laboratory?  
_________________________________________________________________
______________________________________________________ 
c. How long, on average, is the specimen stored before being sent to the 
laboratory?  
i. Hours, mention (_____________) 
ii. Days, mention (_____________) 
d. How long does it take for the specimen to reach the laboratory? 
i. Hours 
ii. Days, mention(_______) 
e. How long does it usually take for results to be reported once a specimen has been 
received?  
i. Hours 
ii. Days, mention (________) 
f. How are results reported to the clinic or the health-care facility? 




v. Others, mention please ___________________ 
14. How many cultures were performed during the last year (2016) or other relevant period 




15. How many cultures were positive? For the same period 
(_________________________________________) 
16. What proportion of TB cases is confirmed by culture? For the same period 
(_____________________) 
Numerator: number of positive cultures identified during a specified period 
Denominator: total number of cultures performed during the same period 
17. How many DSTs were performed during the last year (2016) (or other relevant period of 
time)?  
(_____________________) 
18. Is Xpert MTB/RIF testing available? 
a. Yes 
b. No   End of this section 
19. Is there a clear algorithm or standard operating procedure for staff to follow when using 
the Xpert MTB/RIF test? 
a. Yes 
b. No  
20. How many Xpert MTB/RIF tests were performed during the last year (2016)? (or other 
relevant period of time)?  
(__________________________________) 
21. How many Xpert MTB/RIF tests were positive for TB? For the same period 
(__________________________________) 
22. How many were positive for rifampicin resistance? For the same period 
       (__________________________________) 
 
 
Part (3) Assessing the quality of TB diagnoses 
Location:   Health care facilities providing TB care. 
Staff to be interviewed: health-care staff providing clinical care 
1. Are standards for the diagnosis and case-management of patients with TB available in the 
facility? 
a. Yes  
b. No 
c. Not sure 





e. Others (mention please) _______________ 
3. Do the health professionals at the health facilities visited use (DOH-DOT) standard to establish 
the diagnosis of TB? (It will be appropriate to discuss this with the staff and to look at the files of 
patients diagnosed with TB at the health facility.) staff to be interviewed and records to be 
verified 
a. Always   
b. frequently 
c. Sometimes 
d. Not sure 
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4. Is the diagnosis of smear-positive pulmonary TB established by following the procedures 
specified in the mentioned guidelines? 
a. Yes 
b. No 
5. Are pulmonary TB cases with sputum smear positive confirmed by:  
a. Sputum culture test     
b. Xpert MTB/RIF test   
c. Both 
d. None      
6. Which of the following criteria are used to diagnose smear-negative pulmonary TB? MCQ 
a. History of prolonged exposure to active PTB case 
b. Clinically 
c. Radiological (chest x-ray) 
d. Other radiological imaging (example: CT chest) 
e. Bacteriological culture 
f. Others (mention please) ________________________________ 
7. What procedures are used to establish the diagnosis of extra-pulmonary TB? MCQ 
a. Clinically  
b. Radiological imaging  
c. Biopsy for histopathology 
d. Disease site sample sent to direct smear microscopy 
e. Disease site sample sent to culture for AFB (Acid Fast bacilli) 
f. Others (mention please) ________________________________ 
 




9. For what proportion of patients with extra-pulmonary TB was the diagnosis based on the results 
of histopathology? (Check patient records or HCF documents related to Extra Pulmonary TB 
patients, the reference year is 2016) 
a. All suspected extra Pulmonary TB patients  
b. Majority (More than 50% of the suspected cases) 
c. Few (not many but more than one of the suspected cases) 
d. None of the suspected extra Pulmonary TB patients. 
e. Not sure 
 
10. For what proportion of patients with extra-pulmonary TB was the diagnosis based on the results 
of bacteriological tests? (Check patient records or HCF documents related to Extra Pulmonary TB 
patients, the reference year is 2016) 
a. All suspected extra Pulmonary TB patients  
b. Majority (More than 50% of the suspected cases) 
c. Few (not many but more than one of the suspected cases) 
d. None of the suspected extra Pulmonary TB patients. 








Part (4) Assessing activities addressing childhood TB 
Location:   Health care facilities providing TB care services including case detection, reporting, 
management, or follow up. 
Staff to be interviewed: health-care staff providing TB care services. 
 
1. Are the standard operating procedures or guidelines on childhood TB available at the health 
facilities visited? (observe) 
a. Yes 
b. No 
c. Not applicable, mention why:________________________________________ 





3. What criteria are used to establish the diagnosis of childhood TB? (Pediatrician need to be 
interviewed if available) MCQ 
a. Clinical 
b. Radiological (chest x-ray) 
c. TST 
d. IGRA in children above 5 years of age  
e. sputum smear and culture for  Mycobacterium TB 
f. Sputum Xpert MTB/RIF test  
g. Others (mention please) ______________ 
 
4. Are the procedures to establish the diagnosis of TB in childhood clearly described in the patients’ 
files? (check patient’s file) 
a. Yes 
b. No 
c. Not applicable 




3. Not applicable (no children screened as contacts to active TB case in 2016) 
6. Is isoniazid preventative therapy (IPT) administered to children who are HIV-positive but do not 
have active TB. 
a. Yes 
b. No 
c. Not applicable (no HIV-positive cases seen in 2016 in childhood) 
 
7. Since it is hard to convince a child to take many anti-TB medications for 6 - 9 months and it is 
stressful for a child to be put on isolation for TB, is there any evidence of providing social and 
psychological support for children diagnosed to have TB? ( check records) 
a. Yes 
b. No 
c. Not applicable ( no cases seen in 2016 in childhood) 





c. Not applicable ( no cases seen in 2016 in school age) 
 
 
Part (5) Assessing the management of TB cases 
Location:   Health care facilities providing TB care services including case detection, reporting, 
management, or follow up. 
Staff to be interviewed: health-care staff providing TB care services. 
1- Is patient information entered in the electronic infectious disease notification using HAAD 
recommended case definitions? (check notifications from the facility or check records) 
a. Yes 
b. No 
2- Are the criteria used to categorize TB patients aligned with these definitions? (check notifications 
from the facility or check records) 
a. Yes 
b. No  
3- Is there a complete address or other information for contacting each patient (in TB register or on 
Electronic infectious disease notification submitted by the facility on HAAD system? Check 
notifications or check records)  
a. Yes 
b. no 




5- Are the cards kept under appropriate conditions ( e.g.in patient file)? observe 
a. yes 
b. No 
6- Are TB confirmed cases tested for HIV? 
a. Yes 
b. No 
7- How is treatment for TB administered?  
a. Using DOT strategy  
b. Using other routine procedure   Go to question 17 
8- Is this a DOT providing facility? 
a. Yes 
b. No       Go to question 17 
 
9- How many patients are registered to receive DOT on the day of visit?  
( _______ ) 
10- At what place is the DOT delivered?   
a. At a hospital,  
b. At a health care facility,  
c. others: ________________________ 
i. in the community,  
ii. within the patient’s family home,  
iii. in the school 
iv. in the labor camp  
 
11- For how long is the DOT treatment provided? 
a. Throughout the whole course of treatment,  
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b. Only during the intensive phase 
c. Until the patient discharged from the visited hospital  
12- Are there differences for delivering DOT to patients with MDR-TB?   
a. Yes   
b. No, it is the same    c.  Not applicable, why _____________________ 
13- If yes, please clarify how it is differs: ____________________________________ 
__________________________________________________________________ 
14- Are treatment supporters used? Treatment supporter is a person could be a family member, friend, 
partner, school health nurse, labor camp nurse or any other person who can observe the patient 
during swallowing his ATT medication regularly) 
a. Yes 
b. No  Go to question 17 
15- Are treatment supporters trained or educated on how to observe patient under DOT?  
a. Yes, how? ______________________________________________ 
b. Not trained 
16- Are they supervised by a health care worker from the visited facility?  
a. Yes, how? ______________________________________________ 
b. No 
17- Are the follow up investigations done on time as per DOT – HAAD standard ( on initial 
diagnosis, 3 months, and at the treatment completion)  check patient records  
a. Yes, on time 
b. Yes, done but not on time as per DOT standard 
c. No follow up investigations done  Go to question 20 
d. Not applicable     Go to question 20 
18- What type of follow up investigations done at 3 months of starting treatment? MCQ 
a. Clinical assessment 
b. Sputum smear 
c. Sputum culture 
d. Chest x-ray 
e. Other ( mentioned) -------------------- 
19- What type of follow up investigations done at treatment completion: MCQ 
a. Clinical assessment 
b. Sputum smear 
c. Sputum culture 
d. Chest x-ray 
e. Others ( mention please) -------------------- 
20- Do TB treatment cards include information on: 
a. case notification number                    Yes   No 
b. referral to other facility                   Yes    No 
c. date of starting ATT under DOT program       Yes    No 
d. date of starting continuation phase,           Yes        No 
e. regime used in the initial phase           Yes    No 
f. regime used in the continuation phase                       Yes    No 
 
21- What is the procedure for recording which anti-TB medicines have been administered?  








22- Were patients who defaulted or failed treatment appropriately managed? and how? 
(Review the treatment cards for a selection of patients.) 
______________________________________________________________________________
______________________________________________________________________________ 
23- What is the process used for patients who are transferred to another DOT clinic (to continue 




24- What is the process used for patients who are transferred to another TB management unit (to 





25-  Is there a form that is used when a patient being treated is transferred out (outside UAE)?  




26- Are the treatment outcomes for patients who have been transferred communicated to the initial 
basic management unit? 
a. Yes 
b. No 
c. I don’t know 
27- Is there a system for contacting patients who do not collect their medications or present to a 
health facility on their scheduled appointment?  
a. Yes 
b. No Go to question 31 
 
28- How tracing of defaulters (loss to follow up) is carried out? Check records and provide evidence 
(e.g. copy of calling registration) MCQ 
a. Calling the patient 
b. Calling the treatment supporter 
c. Calling a closed family member to the patient 
d. Calling the sponsor 
e. Others___________________________________________________  
 
 
29- Who conducts the default tracing? MCQ 
a. IC nurse 
b. DOT focal point 
c. Appointment section at the HCF 
d. Patient affairs 
e. Others ( mention please) _____________________________________ 
30-  When is the default tracing undertaken?  
a. After each no-show visit 
b. After the 2nd no-show visit 
c. After the 3rd no-show visit 
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d. Others (mention please) ____________________________________ 
   
31- Is psychosocial support offered to patients to ensure adherence to treatment? 
a. Yes,  
b. No   End of the section 
32- Is such a support offered to all patients or only to specific categories of patients?  
a. To all patients 
b. To specific categories of patients (when there is a need for psychosocial support) 
33- How is such support funded? 
a. Self-pay 
b. Health insurance company 
c. Sponsor of the patient 
d. Civil organization, mention ______________ 
e. Others mention _______________________ 










Part (6) Assessing the programmatic management of drug-resistant TB: 
Location:   Health care facilities providing TB care services including case detection, reporting, 
management, or follow up. 
Staff to be interviewed: Review the programmatic management of drug-resistant TB patients 
with the TB team (physician, nurse, pharmacist, lab. technician if needed). 
 
1- What is the size of MDR-TB problem locally?  
a. Significant problem 
b. As expected 
c. Rare 
Describe if possible ______________________________________________ 
2- How many cases of MDRTB were detected during the 2016 at the visited facility? Check records  
(______________) 
1- How many patients with MDRTB are presently being treated at the facility? Check records 
(______________) 




3- Is there diagnostic capacity for detecting drug-resistant TB – for example, are diagnostics 
available (Sputum Xpert MTB/RIF test or Drug Susceptibility Testing)?  
a. Yes 
b. No    skip next question 





c. Not applicable 
5- Are patients with MDRTB referred to other facilities designated by   HAAD-DOT program? 
a. Yes 
b. No 
c. Not applicable ( no patients with MDRTB detected for the last 2 years) 
 
6- What proportion of specimens from new TB cases undergo DST? Check for TB cases seen in 
2016 
a. All 
b. Majority (more than half of the cases) 
c. Few (not many but more than one) 
d. None 
7- How are laboratory confirmed MDR-TB patients treated?  
a. Under DOT with strict follow up 
b. Under DOT with regular follow up 
c. Regular follow up visit without DOT 
d. Treatment is not available in this facility 
e. Others, mention _______________________________________   
 
8- Are second-line anti-TB medicines available?  
a. Yes    
b. No   End of the section 
     
9-    Which type of treatment is used for MDR-TB patients:  
a. Hospital-based    
b. Community-based?        End of the section 
c. Not Applicable  End of the section 
 
10- If MDR-TB patients are treated in hospital,  
a. Is there capacity to provide respiratory isolation for patients who remain culture-positive 




b. Are TB infection-control measures in place for the isolation facilities? Observe and verify 
i. yes 
ii. No   
  
Part (7) Assessing TB/HIV collaborative activities: 
 
Location: TB units and HIV units, or points where service delivery is integrated, at the health-facility 
level or point-of-care level. Administrative offices deputed to plan and manage TB/HIV collaborative 
activities 
Who should be interviewed: meet the focal points for both TB and HIV program at the HCF or the 
healthcare professionals responsible of delivering related services. Meet providers of health services at 
delivery points or the infection control staff. 
 
A)  Review TB/HIV policy and guidelines 
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1. Are the facility team aware about HAAD circular (DG/67/13) dated 12/Nov. 2013 regarding HIV 
testing for confirmed TB cases? Check documents, 
a. Yes 
b. No 
2. Are all confirmed TB patients tested for HIV? Check samples from facility TB records or 
notifications. 
a. Yes  
b. No   Go to question 5 
c. Partially  
3. Where they are tested?  
a. At the same facility 
b. Referred to another facility where the test is available (mention the facility please) 
_________________________________________ 
4. How often they are tested:  MCQ 
a. At the initiation of treatment 
b. Monthly throughout the treatment course 
c. At the end of the treatment course 
d. Others:__________________________________  
5. If the uptake of HIV testing is low, where are the bottlenecks or what are the challenges to 
scaling-up HIV testing for TB patients? 
a. Rejection from the patient 
b. Difficulty in obtaining the patient consent 
c. Unavailability of the test 
d. Others__________________________________ 
6. Do you have HIV positive TB patient managed in this facility for the year 2016? 
a. Yes 
b. No   Go to question 9 




8. Is early ART (Antiretroviral Therapy) given to HIV-positive TB patients within 8 weeks of 
starting TB treatment? 
a. Yes 
b. No 
9. Are people living with HIV screened for TB each time they visit a health facility? 
a. Yes 
b. No 
c. Not applicable 
10. Is isoniazid preventative therapy (IPT) offered to people living with HIV after active TB disease 
has been ruled out? 
a. Yes 
b. No 
c. Not applicable 
 
 
B) Review TB/HIV collaborative mechanisms: 






c. Not Applicable 
12. Are there any arrangements in place to ensure that HIV care and treatment continue for HIV-
positive patients after they complete treatment for TB? 
a. Yes, describe:_______________________________  
b. No 
c. Not applicable 
 
 
C) Review TB/HIV activities at facilities providing HIV services: 
13. Are people living with HIV routinely screened for TB? Check records of people living with HIV? 
a. Yes,  
b. No    Go to question 17 
c. Partially 
d. Not applicable  Go to question 17 
14. If yes, where they are screened? 
a. At the same facility 
b.  Referred to another facility where the test is available (mention the facility please) 
___________________________  
 
15. How often they are screened? (Review and describe the approach.) MCQ 
a. At the initiation of treatment 
b. quarterly throughout the treatment course 
c. once the patient develop suspicious signs and symptoms 
d. Others:_____________________________ 
b. Not done 
c. Rarely done 




17. If TB screening was not done, was rarely done or was poorly done, what are the main reasons? 
a. Rejection from the patient 
b. Difficulty in obtaining the patient consent 
c. Unavailability of the tests 
d. Financial issues 
e. Others__________________________________ 
 
18. What are the main concerns about diagnosing TB in patients who are HIV positive? 
_________________________________________________________________________
__________________________________________________________________ 
19.  Are measures in place to control the spread of TB infection in facilities caring for HIV-positive 
patients or in facilities offering integrated TB services and HIV services? (observe and verify) 
a. Yes 
b. No 
20. Are there any concerns about infection control in these facilities? 










Part (8) Assessing patients’ adherence to TB treatment: 
 
Location: hospital ward, TB outpatient clinic (daily OPD or infectious disease clinic)  
Who should be interviewed: If possible, interview a selection of inpatients and outpatients and review 
their treatment cards. Patients should be told that the interview is voluntary, that any information provided 
will remain confidential, and that permission will be asked before photographs are taken. The 
recommended number of patients to be interviewed at each facility is two or three. 
 
1- How well do health workers communicate with patients? (Observe communication between 
health workers and patients, and the attitude of health workers towards patients.) 
a. Fine communication 
b. Acceptable  
c. Poor communication 
d. Others:___________________________ 
2- Do patients know that they are being treated for TB or for MDR-TB (if relevant)? 
a. Yes 
b. No 
3- Do patients know how long their treatment for TB will last? 
a. Yes 
b. No 
4-  Do patients take their medication while they are being directly observed? 
a. Yes 
b. No 
5- Is treatment convenient for the patient in terms of the time and location? 
a. Yes 
b. No 
6-  Do patients take their medication regularly?   
a. Yes 
b. No  
 
7- How many doses were missed during the past month?   
______________________________________________________________ 
8- What are the main issues that affect whether a patient follows the treatment plan? for example, 
has the patient had any  
a. adverse effects,  
b. problems with deliveries of medicines or DOT services,  
c. transportation issues 
d. problems at work   
e. others:___________________________________________ 
9- Are the treatment cards correctly filled and used? 
a. Yes 
b. No 
c. Partially  
10- Do patients in the continuation phase know about the schedule for follow-up sputum 





c. Partially  
11-  Do patients pay for their anti-TB medicines or other health-facility fees? 
a. Yes, total payment 
b. Partial payment 
c. No payment 
12- Do patients incur other costs directly related to their disease (for example, for tests and 
medicines, and for managing adverse reactions)? 
a. Yes, total payment 
b. Partial payment 
c. No payment  
13- Has the patient ever been treated for TB in the past: 
a. Yes 
b. No 
c. Can’t re-call 




15- Have patients received health information about their disease, treatment and prognosis? 
a. Yes 
b. No 
c. Partially  
16- Do they understand the information that they were given? 
a. Yes 
b. No 
c. Partially  
17- Do patients feel that the health-care services satisfactorily address the emotional and spiritual 
suffering that results from the disease and its treatment? 
a. Yes 
b. No 
c. Partially  
18- Do patients feel that their privacy is respected when they interact with the health services? 
a. Yes 
b. No 
c. I don’t know 
19-  Do patients receive any incentives or enablers to continue treatment (for example, food, transport 
vouchers or money)? 
a. Yes 
b. No 
20- What do patients’ families and people in their communities think about TB (interview companion 
of TB patients if possible) 
a. Disease that can be cured 
b. Disease troubling their life  
c. Disaster  
d. Stigma 
e. Others:_________________________________________________ 







Part (9) Assessing the management of anti-TB medicines and supplies: 
Location:     pharmacies at HCF or TB clinics 
Staff to be interviewed: TB coordinators or TB focal points, pharmacists, staff at the medicine and 
supply unit. 
 
1. Who is in charge of ordering and receiving anti-TB medicines and supplies?  
• Mention the job title and position (___________________________________________) 
2. If the person is available, ask about the procedures used to verify and document the quantities 
received (regarding anti TB needs and supplies as part of the general items) 
______________________________________________________________________________
__________________________________________________________________ 
3. Does the facility use a register (or automated system) for medicines or supplies to track the 
delivery, receipt and movement of each item? Check and verify 
a. Yes 
b. No 
4. Are expiry dates monitored? Check and verify 
a. Yes 
b. No 
5. Where are orders for medicines and supplies fulfilled? 
a. from a regional store   
b. central store,   
c. directly from suppliers or wholesalers 
d. others, please describe from where __________________________ 
6. What procedures have been established to ensure that health facilities receive medicines and 
supplies regularly?  
______________________________________________________________________________
______________________________________________________ 
7. How often are supplies received?  
a. Monthly 
b. Quarterly 
c. On need 
d. Others, describe_______________________________ 
8. Who determines what supplies are needed and places the order? 
a. Pharmacist in charge 
b. Infectious disease physician 
c. DOT focal point 
d. Others, mention please___________________________  
9. Are first-line anti-TB medications available?  
a. Yes,        













11. Are second-line medicines available?  
a. Yes 
b. No   skip next question 
12. Which of the second line ATT medicines are available? 
a.  ________ 
b.  ________  
c.  ________ 
d.  _________ 
13. Is there a buffer or safety stocks of anti-TB medicines?  
a. Yes,    
b. No   skip next question 
14. How long should the buffer stock last? 
a.  1-3 moths 
b. 4-6 months 
c. More than 6 months 
15. What anti-TB medicines are available for children?  
________________/________________/_________________/__________________ 
16. Are pediatric formulations available? 
a. Yes    End of the section 
b. No,  








Part (10) Assessing recording and reporting 
Location: HCF dealing with TB cases detection, reporting, management and follow up. 
Staff to be interviewed:  Health care staff dealing with case reporting or infection control staff  
1. Are the following recording and reporting (hard copy or electronic) forms available and used at 
the healthcare facility level? (circle the answer) 
a. Request form for sputum-smear microscopy examination;   Yes  No 
b. Request forms for culture and DST (if relevant);   Yes  No 
c. TB treatment card;      Yes  No 
d. TB treatment referral or transfer-in form;    Yes  No 
e. Register of patients suspected of having TB;   Yes  No 
f. Register of TB contacts      Yes  No 
2. Is electronic system for reporting in place? 
a. No, completely paper-based 
b. Yes, for all TB patients (suspected and confirmed PTB and Extra PTB) 
c. Yes, only for certain TB patients (specify)_______________________ 




4. Do you have a valid account on electronic -Infectious disease reporting system of HAAD? 
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a. Yes   check at least the  account of the staff interviewed 
b. No 
5. Are you aware with the stages in the TB notification sub form on HAAD electronic system? 
a. Yes 
b. No  Go to question 8 
6. How many stages are in the TB sub form on the electronic system: 
a. 1 stage 
b. 2 stages 
c. 4 stages 
d. 6 stages 
e. More than 6 stages 
 
 
7. Are stages in the TB notifications sub forms are filled in due time? Check 2-3 notifications 
submitted by the facility from the year 2016 
a. 2nd  stage only 
b. 2nd  and 3rd  stage only 
c. 2nd -4th  stage 
d. 2nd -5th  stage 
8. Is regular reports for TB cases enrolled in DOT are submitted by the TB focal point or infection 
control staff to CDD/HAAD regional office? 
a. Yes,   Go to next question 
b. No   End of interview 
9. If yes, is that on regular basis? 
a. Yes     
b. No      
10. If yes, at what day of the month the report for the previous month is submitted? Check sample of 
the report (excel sheet) and obtain copy of the report 
Day number ______  
11. Are the data for TB cases in the regular report are updated on monthly bases with the patients 
follow up data? Check at least last report submitted by the facility and compare it with the 
patient’s file 
a. Yes 













Part (10) Assessing infection control 
Location:  outpatient clinic at a health facility, hospital ward, HIV-care clinics, any health facilities that 
see TB patients or patients suspected of having TB, 








2. Is focal person for TB infection control identified? 
a. Yes 
b. No 
3. Are health workers been trained in infection–control procedures? 
a. Yes 
b. No 
4. Are health workers practicing infection–control procedures? Observe and verify 
a.  Yes 
b. No 
c. partially 
5. Is there any separation of infectious patients (including suspected or confirmed TB 
patients) from non-infectious patients in the waiting area? Check and verify 
a. Yes 
b. No 
6. Is cough hygiene policy established for education of patients? Check for evidence 
a. Yes 
b. No 
7. Is surveillance for TB among health-care workers established? 
a. Yes 
b. No  skip next question 
8. If yes, how often:  
a. One time 
b. Yearly 
c. Others____________________  
 
 




10. Are health workers educated about the signs and symptoms of TB, and TB infection-
control procedures? Ask and verify 
a. Yes 
b. No 
11. Are appropriate Ventilation systems available in high risk area (ER, Lab, infectious disease 
clinic, Isolation ward)? 
a. Yes 
b. No   skip next question 
c. Partially 
12. Are ventilation systems functioning well? 
a. Yes 
b. No 
c. Partially  













Part (11) Assessing public–public and public–private mix approaches: 
This part should be filled whether the facility is public or private 
Location:  TB clinics or outpatient clinic in private health care facilities and public- healthcare facilities 
Staff to be interviewed: health care professionals at private and public healthcare providers 
 
1. Are operational guidelines on public–private mix approaches (coordinating procedures for TB 
patient referrals and follow up) available from the HAAD-DOT program?  
a. Yes 
b. No  skip next question 
c. Not applicable skip next question 
2. If yes, are they used? 
a. Yes 
b. No 
c. I don’t know 
3. Have sensitization and training activities been conducted for public-private coordination in 
detection and management of TB patients? 
a. Yes, when _______________________ 
b. No 
c. Not applicable 
4. How do they collaborate with the HAAD-DOT program or the reference lab for sputum culture? 
______________________________________________________________________________
______________________________________________________________________________  
5. Is this facility private? 
a. Yes 
b. No    End of interview 
6. If yes, do facility laboratories have the resources for diagnosing smear-positive TB patients? 
a. Yes 
b. No  
7. Do facility laboratories have the resources for diagnosing patients with MDR-TB? 
a. Yes 
b. No  
 
8. Do private practitioners treat patients with confirmed TB disease? 
a. Yes 
b. No 
9. Are anti-TB medicines, including first or second-line medicines, available in private pharmacies? 
a. Yes  
b. No 
c. I don’t know 








TB Evaluation Framework for TB unit 
 
Name of facility:   
Date of the visit:      /     / 2017 
Time: from               To    
 
Visiting team: 
 Name Place of work Mobile No. signature 
1     
2     
3     
4     
Staff from the facility interviewed: 
 Name Place of work Mobile No. signature 
1     
     
Report submitted to CDD/HAAD on      /       /2017 
Received by:    Name & signature 
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Assessing the management of the TB control program 
at HAAD level 
 
Section (A):TB control Strategy 




2. Is there a strategic plan for TB control at HAAD level?  
a. Yes 
b. No  
3. If yes, is the plan consistent with the national strategic plan? 
a. Yes 
b. No  
4. Is the document detailing the national policy to prevent and control TB available at the 
coordination unit (DOT team at CDD/HAAD)? 
a. Yes 
b. No 
5. Are the guidelines produced by the central unit (at MOH level) of the national TB program 
available at the coordination unit? 
a. Yes 
b. No 
6. Is there a standard for the diagnosis, reporting and case-management of patients with TB 
produced by CDD/HAAD? 
a. Yes 
b. No  
7. Is this standard applied? 
a. DOT strategy 
b. Other strategy, ___________________ 
8. Is the standard for establishing the diagnosis of TB aligned with international standards? 
a. Yes 
b. No 
9. Do this standard specify the diagnostic process to be used to identify different types of TB? 
a. Smear-positive pulmonary TB    yes   No 
b. smear-negative pulmonary TB    Yes   No 
c. Extra-pulmonary TB     Yes  
 No 







Section (B): TB/HIV collaborative activities: 
10. Is there a national policy and are there national guidelines on TB/HIV collaborative 
activities? 
a. Yes 





11. If yes, when were both the TB/HIV policy and the guidelines last updated? 
_______________________________________ 
12. Are both the national policy and the guidelines aligned with international recommendations? 
a. Yes 
b. No  
 
Section (C): TB in Childhood 
13. Is childhood TB included in the HAAD standard to prevent and control TB?  
a. Yes 
b. No  
14. Are there any training materials about implementing activities to address childhood TB?  
a. Yes 
b. No  
15. Have specific staff within the central unit been assigned to coordinate activities for childhood 
TB? 
a. Yes 
b. No  
 
Section (D): Funding 




17. Have any local sources of funding been mobilized for TB activities? 
a. Yes 
b. No  




Section (E): Training 




20. If yes, 
a. Are the national training materials produced by the central unit available? 
i. Yes 
ii. No  
iii. Others describe:________________________________________  





c. Is there a current training schedule? 
i. Yes 
ii. No  
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f. Are there any reports from these sessions? 
i. Yes 
ii. No  
g. Does the coordination unit use the training programs developed by the central unit of 
the national TB program? 
i. Yes 
ii. No 
iii. Others, mention please 
______________________________________________________________
______________________________________________________________





Section (F): Supervision 
21. Does the coordination unit organize supervisory visits to health care facilities?  
a. Yes 
b. No  
22. If yes, 
a. Is the national guideline describing how to conduct a supervisory visit available? 
i. Yes 
ii. No  
b. Which staff members supervise TB care and control activities at the health facilities? 
____________________________________________________________________
_________________________________________________________________ 
c. Have these staff members been trained to undertake supervisory visits? 
i. Yes 
ii. No 




e. For which time period has this schedule been established? 
i. for a quarter,  
ii. fora semester or  
iii. for a year 
iv. others ___________________________________________ 







g. How many supervisory visits were carried out and how many were planned during 
the period covered by the previous schedule (year 2016)? 
__________________________________________________ 
h. Are reports from supervisory visits available for the period covered by the previous 
schedule? 
i. Yes 
ii. No   Go to question (l) 
 




j. Were the recommendations clearly identified?  
i. Yes 
ii. No 





l. How often was the coordination unit visited by staff from the national TB program’s 
central unit during the past 12 months? 
___________________________________________  
m. Are reports of the supervisory visits conducted by staff from the central unit available 
at the coordination unit?  
i. Yes 
ii. No    skip next question 
n. If yes, are these reports the same as those at the central unit? 
i. Yes 
ii. No  
23. Are meetings organized regularly by the coordination unit with health-care workers providing 
TB care and control services? 
a. Yes 
b. No     Go to question (27)   









26. Are notes taken at each meeting?  
a. Yes 
b. No 
(The reviewer should check notes from the meetings and record the issues that were raised.) 
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27. Are there any mechanisms in place to ensure that services are coordinated with partners that 
are locally involved in TB efforts? 
a. Yes 
b. No    Go to section (G) 
28. If yes, who are these partners? 
a.     b.     c.     d.        
 
29. How are services coordinated with other care providers, particularly those who are practicing 






Section (G): Recording and reporting: 
30. What is the type of system used for recording and reporting TB cases at the HCFs level? 
a. Paper based 
b. Electronic 
c. Others _______________________________________  
31. Is Electronic system at HAAD level in place? 
a. Yes, for all TB patients  
b. Yes, only for certain TB patients (specify) ____________________________  
c. No, completely paper-based   Go to question 34 
32. How far is the coverage of the electronic system? 
a. Complete Abu Dhabi emirate coverage 
b. Partial geographical coverage 
c. Excludes certain facilities (for example, prisons, military facilities, general hospitals, 
private clinics) 
d. Excludes private sector (give more details: _________________________________ 
) 
33. If an electronic system is in place, specify the type: 
a. Web-based (via Internet browser) 
b. Installed software, open-source 
c. Installed software, not open source 
d. Installed software, other 
e. System based on paper or transfer of worksheets (for example, Excel pages) 
34. Does the dataset in the reporting system include minimal information about? 
a. notification by age and sex,      Yes  No 
b. address and contact details     Yes  No 
c. type of TB, ( by site of the disease)    Yes  No 
d. patient’s clinical symptoms      Yes  No 
e. diagnosis category      Yes  No 
f. information on sputum conversion      Yes  No 
g. treatment category      Yes  No 
h. TB determinants       Yes  No 
i. Lab. results, including results from sputum smear and culture,   Yes  No 
j. Xpert MTB/RIF test       Yes  No 
k. DST        Yes 
 No 
l. HIV test       Yes  No 
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m. Treatment monitoring and follow up,    Yes  No 
n. treatment outcomes     Yes  No 
 
35. Are all data from TB activities carried out at the intermediate level (HCFs level) available at 
the coordination unit (DOT team /CDD/HAAD)? 
a. Yes 
b. No     Go to section (H) 
36.  If yes, 
a. Through which channels are data received from the peripheral DOT clinics and other 
health facilities? 
i. Excel sheet by email 
ii. Mail 
iii. Fax 
iv. Others ___________________________ 
 
b. Are these data sent over the Internet or through other administrative channels 




c. What is the kind of system used for compiling data? 
i. paper-based  
ii. computer-based 
 
d. Are the data  
i. aggregated  
ii. case-based 
iii. both 
e. Is the dataset model used in the coordination unit (DOT team at CDD/HAAD) similar 
to that used in the national program’s central unit?  
i. Yes 
ii. No  
f. Are data on TB and TB prevention, care and control collected and compiled in other 
information systems that are not connected to the national program? 
i. Yes, describe ____________________________________ 
ii. No  
g. Are data analyzed regularly (MCQ)? 
i. Yes 
ii. No     Go to section (H) 
 
 
    














j. Are these reports communicated to the entities that need to be informed (for example, 
to health-care staff, partners, and primary health-care services)?  
i. Yes 
ii. No     skip next question 




l. Are these reports and data discussed at meetings regularly organized by the 
coordination unit (DOT team at CDD/HAAD)? 
i. Yes 
ii. No  
______________________________________________________________
______________________________________________________  
Section (H): Contact Management 
37. Is the TB control team at CDD/HAAD involved in contact tracing? 
a. Yes 
b. No  
38. If yes What  are they involved in the following contact tracing activities: 
a. Putting the schedule for contact screening   Yes No 
b. Identify the case where contact screening is indicated Yes No 
c. Identifying the exposed contacts    Yes No 
d. Referring the contact for screening    Yes No 
e. Screening the exposed contacts    Yes No 
f. Receiving the results     Yes No 
g. Follow up of LTBI treatment     Yes No 
39. Is there any staff within the TB control team at CDD/HAAD assigned for contact tracing? 
a. Yes  
b. No  
40. How the TB control team at CDD/HAAD identifies the exposed contacts? 
a. By interviewing the patient or family member 
b. By calling the patient 
c. By calling the sponsor or family member 
 
Section (I): Human resources: 
41. What are the human resources requirements for different tasks associated with the   TB 




______________________________ (for more information can use the back of this page) 













44. Are there enough staff?  
a. Yes 
b. No  




46.  Are there any human resources gaps in terms of the number of staff required – that is, will 
more staff be needed as the program expands and staff take on additional roles and 
responsibilities?  
a. Yes 
b. No  
47. Are there any gaps in the quality of staff that is, do the knowledge and skills of staff need to 






48. Are there enough appropriately skilled staff to implement the proposed work-plan? 
a. Yes 
b. No 
c. Partially  




_________________________________________________________________   
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Recommendations for TB Control Program and Policy Improvement 
The previous chapters provided rich information about the tuberculosis control program in Abu 
Dhabi. A detailed epidemiology is provided to understand change over time and the most affected 
subgroups of the community, followed by a discussion of TB diagnosis and the adoption of a new 
rapid PCR test in screening programs for expatriates, and ending with a qualitative review and 
evaluation of the program in its various stages in the Emirate.  
This section is intended to provide some feedback and recommendations to improve the 
effectiveness of the program in future.  
It is clear from the review that tremendous efforts and resources were put into the TB screening 
and early detection program. This was clear in national and local policies that clearly identified 
requirements for detailed screening and reporting. One of the strengths identified in the program 
in Abu Dhabi is the electronic reporting system that captures data and provides policymakers with 
the information needed for decision-making purposes. However, additional effort is required in 
the next years to strengthen procedures for the treatment of TB DOTs and to improve access for 
high-risk groups. The following are details of opportunities to strengthen the performance of the 




Planning and TB Policy  
The evaluation provided some feedback about the current performance of the central program unit 
and identified some areas for improvement. The program requires additional work to strengthen 
preventative measures for children by providing clear guidelines and training healthcare staff on 
the screening, prevention and management of TB in children. The link between the TB/HIV 
program can be further strengthened by having collaborative activities and joint guidelines. The 
lack of budget for TB awareness clearly affects the overall performance of the program. 
Collaboration with other health, non-profit or private organizations to work with DOH and 
participate in awareness activities is needed. A revision of human resources is required in terms of 
staff numbers needed to ensure an adequate workforce to cover the daily functions of contact 
tracing, field visits, training, and awareness activities. It is clear from the review that the program 
has good KPI measures that cover process and outcomes. This, however, can be further improved 
by setting targets by 2020 in comparison to 2015 for decreases by 20% in burden of TB, and 35% 
in mortality associated with TB. This study provides baseline data for the year 2015 that can be 
adopted and monitored in the future.  
  
Case Detection 
Early detection of cases is a very important element of the TB control strategy and the review 
confirms that this is one area of the strength in Abu Dhabi. The visa screening services have good 
elements of screening and cover adult expatriates that comprise the majority of the population. 
Access by the private sector for confirmation of suspected cases by referral of samples to the 
central lab is good practice in identifying potential cases. Some practices in primary health care 
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settings, such as areas of sputum collection, need to be addressed and improved upon as well as 
stressing the importance in educating health care professionals to develop best practice in the 
suspicion of TB. 
 
Diagnosis and Confirmation 
The first pillar of the WHO Stop TB strategy is to have integrated, patient-centered TB care and 
prevention. In reviewing the system in Abu Dhabi, it is clear that the system has strengths in areas 
of TB care such as the introduction of TB DOT in primary health care settings for better access 
and follow-up for adult patients. However, it is unclear which facility is in charge of patients with 
MDR or XDR and this is a very important component of TB management. Care needs to be taken 
of difficult cases of TB who failed to respond in the first round or patients with MDR or XDR by 
facilities that have the infrastructure and resources needed for the management of those cases. 
They should be clearly identified as reference centers for the management of such patients. 
Testing for second line sensitivity for TB medication is not available in the health care system in 
Abu Dhabi. This is a gap that needs to be closed. This can be done by selecting one lab to be the 
reference lab for TB sensitivity testing. This one lab can cover the needs of the whole emirate. 
This will help healthcare professionals to get specific information needed for a better management 
plan of patients with MDR or XDR. This will also limit the transmission of XDR in the community. 
WHO recommends that programs have population representative data for drug resistance 
surveillance (DRS) that includes new patients, different categories of retreatment patients and 






Preventative Treatment for Latent TB 
It is clear that the national and local programs focus on the treatment of close contacts exposed to 
TB patients and provide them with the proper preventative treatment required. However, the 
program does not elaborate on actions required for patients identified with latent TB. It is estimated 
that around 80% of incident cases are due to reactivated latent TB (11). Studies have found that 
the management of latent TB is a core intervention for TB control (7, 8, 9, 11). 
The introduction of a community-wide preventative treatment for latent TB cases is a big step for 
the health care system in Abu Dhabi that needs to be studied, but it is also a game changing step 
that can reduce the burden of TB priority, especially among expatriates. Based on the available 
data, around 500-1,000 people might require referral from visa screening centers to a TB DOT 
facility for preventative treatment and follow-up. There are options for treatment regimens that 
can be used: the most effective one is weekly, directly-observed rifapentine plus INH (for three 
months). The estimated annual cost of this option will be around 4 million Dirhams for around 
1,000 patients. It is important to engage different stakeholders in the discussion of how this service 
can be provided and what is to be the expected outcome. 
Management and follow-up 
The national and local guidelines follow international standards of care and management of 
patients with TB. The tracking of patient compliance to treatment is an important component of 
the TB control strategy.  The evaluation provided some reasons why patient discontinue  treatment. 
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This can be further studied and improved by improving access and patient education about the 
disease.  
A delay in patient management by more than 90 days is associated with more transmission among 
close contacts, up to 40%, according to some studies (10). Therefore, it is important to ensure that 
confirmed cases get proper admission and management on time. It is important to focus on 
providing good access for TB DOT management for high risk groups such as labor camps by 
designating a clinic that provides TB DOT treatment. Public services provide exclusive treatment 
and there might be access issues for high-risk patients due to the location of those services. A 
suggestion of expanding the treatment to designated facilities in the private sector to improve 
access can be discussed with stakeholders. 
The adoption of modern technologies to improve adherence of patients to treatment is one of the 
effective ways to improve patient compliance. Studies have proven the effectiveness of use of 
mobile video recording applications to enhance TB DOT (19). This option can be discussed based 
on budget availability for the enhancement of the control program. 
 
Tuberculosis in Children 
Prevention 
Measures to prevent TB in children include screening of children who have been exposed to TB 
patients and providing them with necessary TB preventative medication. It is clear that contact 
tracing in children is currently separated from adult services and is only provided by tertiary care 
hospitals. Care providers must increase access for preventative services for children. 
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Management of Cases 
Guidelines for the diagnosis and management of TB are currently unavailable but could be 
developed as an attachment to the national guidelines. In addition, a careful revision and definit ion 
of services that provide TB treatment for children must be carried out to ensure that cases with 
MDR or XDR are referred to a tertiary care facility for proper management. 
 
TB Awareness and Collaboration  
In order to change and upgrade the TB control program successfully, it is important to engage 
various stakeholders and discuss with them the options of how to make change happen and to 
persuade them to adopt one common plan. It is important to have a Public/Private partnership plan 
and to obtain the support of the private sector to ensure success. 
Table 1, below, shows the main areas of change required and stakeholder mapping. 
 
 
Table1: Summary of Action plan and stakeholders required  
Objective Key Action Stakeholder Action time-line 
Improve preventati ve 
and curative treatment 
in Children 
Revise TB guidelines and 
cover TB care for children 
DOH, MOH Short term 
Identify primary health 
care centers that can 
provide preventative & 
follow up for TB care for 
children 
DOH, SEHA Intermediate 
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Improve TB awareness  Create a program for TB 
awareness in collaboration 
with stakeholders 
DOH, All stakeholders Short term 
Revise TB program 
KPIs 
Set targets for TB 
reduction based on WHO 
End TB Strategy 2015 
DOH, MOH Short term 
Improve access to 
treatment among high 
risk groups 
Mapping of cases of TB 
for the last three years in 
comparison to DOT 
clinics 
DOH Short term 
Use of mobile application 
to track patient 
compliance to treatment 
DOH, SEHA Intermediate 
Introduce TB management  
in designated private 
facilities 
DOH, Private sector Intermediate  
Drug Resistance 
Surveillance  
Define a reference lab for 
MDR/XDR sensitivity 
testing 
DOH, SEHA Intermediate 
Encourage TB Research Define priority research 
areas and request funding 
DOH, MOH, UAEU Long Term 
International 
collaboration for TB 
control 
Establish link with TB 
control program in India 
and Pakistan. Provide 
some supportive funds 







To strengthen the local control of TB, it is suggested that communication be strengthened with TB 
Control Programs in countries such as India and Pakistan who are responsible for most TB cases 
arriving in the UAE. This will have a positive effect on the incoming workforce to the UAE. This  
well-known practice is already implemented in the USA, for example, at the Mexican border to 
control imported cases of TB. Such robust collaboration between countries can help control the  
incidence of TB.  
 
TB Research in UAE 
Research is a very important component of the End TB Strategy defined by the WHO (1,2). 
Varying types of research are required globally to support elimination plans such as innovation on 
diagnosis, technology and prevention. The focus on the local needs in this study identified a few 
priority areas of importance to Abu Dhabi and include the following: 
1- Program-based operational research to follow program effectiveness and provide accurate 
feedback on areas of improvement. 
2- Genetic sequencing to understand more about the epidemiology of TB in Abu Dhabi, UAE. 
This type of research is well known and widely utilized for contact tracing and 
identification of sources of infection in the community. 
3- Cost-effectiveness analysis to support guiding decisions toward most effective 
interventions. 
A collaboration among local authorities and academic institutions is suggested to carry out 
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Professional Profile Public Health Professional with 14 years’ experience and active work in this field. Started 
the profession working in the infectious diseases clinic and progressed in career until 
presently employed as Manager of the Communicable Diseases Department at HAAD. 
Studied as part time for MPH in John Hopkins Bloomberg of Public Health and currently in 
the final stages of my DrPH. Have special interest in knowledge transfer and teaching in 
UAEU as adjunct associate Professor in the Institute of Public Health. Founder and chair 
member of the Editorial Board for the Communicable Diseases Bulletin in Abu Dhabi as 
well as Chair of the Visa Screening Panel, HAAD, Abu Dhabi. Worked in the National level 
as member of national committees for strategic planning of outbreaks and pandemics and 
establishments of the national laws such as the National HIV law in 2010 and other 
regulations related to TB , Visa Screening and Infectious Diseases laws in 2016. 
Board Member of Rahma Association for support Cancer patients. 
 
Education • Adjunct Currently Part time student, DrPH  in John Hopkins  
Bloomberg School of Public Health, USA 
• Public Sector innovation diploma, Cambridge university, UK, 2017 
• MPH, John Hopkins Bloomberg School of Public Health, USA, 2011 
• MBBS, FMHS, UAE University, UAE, 2003 




Professional Experience Manager of Communicable Diseases Department 
Public Health & Research, Health Authority Abu Dhabi, 
Board   
• Active Participation in the strategy of public health and communicable 
diseases 
• Developing awareness programs for infectious diseases and vaccination to 
educate the public 
• update of vaccination program in Abu Dhabi Emirate and adding new 
vaccines 
• participation in review and update of infectious diseases regulations in UAE 
including Infectious diseases law 2014 and visa screening ministerial decree 
2016 
• introducing rapid response for infectious diseases 





• Introducing TB DOT program in the Emirate of Abu Dhabi and later this was 
adopted for the whole UAE 
• Acting Director of Public Health in addition to my job description from Sep 
2014 until July 2015 
• Leading the international collaboration of HAAD with CDC USA 
• Leading Research related to MERS-CoV in UAE in collaboration with CDC USA 
• Leading BSL3 reference laboratory for infectious diseases which is the only 
lab in UAE with this level for human health 
• Setting the Strategic plan for the Department and designing the plans for the 
implementations according to the goals and objectives of the Communicable 
Diseases Department 
• Evidence based decision making for the development and evaluations of the 
existing gaps in the health care system related to the control of infectious 
diseases in Abu Dhabi 
• Leading the operational perspectives of Communicable diseases surveillance 
and monitoring including: E-Notifications, Premarital Screening, Malaria 
Control, Vaccinations and outbreak response and management 
• Active members in several Committees in Abu Dhabi including the 
Disciplinary Committee, Emergency preparedness and response, Tender 
Committee, and Visa Screening Panel. 
• Member of National Committees for the design and regulations of few 
national programs such as HIV national Committee, and Visa Screening 
National Committee  
 
 Section Head, Communicable Diseases  
Public Health & Policies, Health Authority Abu Dhabi 
• Supervise the functions of infectious diseases section including: Visa 
Screening, Infectious diseases Notification, Vaccination programs in the 
Emirate of Abu Dhabi, HIV, Malaria Control, Tuberculosis control  
• Review and analysis of Communicable diseases trends and plan for control 
measures according to the priority of diseases. 
• Evaluation and assessment of infectious diseases surveillance systems. 
• Participated in the review and establishments of several laws in UAE such as 
the Visa Screening Laws 2010, HIV law 2010 and Public health law 
• Part time student in MPH- DrPh in Bloomberg School Of Public Health 
• Member of the Disciplinary Committee in HAAD which review cases related 
to the medical practice and decide on the actions and penalties for medical 
errors. 
• Member of HAAD Emergency Command Center in charge of planning for 












Public Health & Policies, Health Authority Abu Dhabi 
• The lead of Visa screening program in Abu Dhabi 
• Participated in the development of Visa screening standards for the Emirate 
of Abu Dhabi 
• Design and implementation of Visa Screening electronic system 
• Development of the electronic logic matrix for decision of fitness without 
human interference. 
• Set out HIV response plan in Abu Dhabi in coordination with UNDP 
• Lead the infectious Diseases Surveillance system and prepare the regular 




 Head, Infectious Diseases Control Section  
Preventive Medicine, General Authority of Health Services 
• Handling suspected and confirmed infectious diseases cases from visa 
screening 
• Coordination and communication with MOH and MOI in relation to positive 
HIV and TB cases 
• Supervise the treatment and follow up of Contacts of infectious diseases 
• Epidemiological investigation of certain infectious diseases of interest for 
possible outbreak 
• Prepare the regular reports about infectious diseases status in the center 
• Counseling of HIV cases notified and arrange for the referral and 
management 





Teaching Experience  Adjunct Assistant Professor in the College of Medicine and Health Sciences, 
UAE University, October,2013 
• Assisted in teaching of Epidemiology for Managers Course for Students 
in Masters of Health Administration, Zayed University in 2011, 2012 
and 2013 
• Assisted in teaching of Senior Clerkship Students specific session about 
Epidemiology of Infectious Diseases in Abu Dhabi, in February and 
May,2013, FMHS, UAEU 
• Excellence in Teaching from UAEU 2014 
Adjunct Associate Professor in the College of Medicine and Health Sciences, 
UAE University, October,2014 
• Assisted in teaching of Epidemiology for Managers Course for Students 
in Masters of Health Administration, Zayed University in 2014 until now 





• Assisted in teaching of Senior Clerkship Students specific session about 
Epidemiology of Infectious Diseases in Abu Dhabi, 2014 until now in 
UAEU 
• Excellence in Teaching from UAEU 2017 
  
Research & Publications  
• Leading the MERS-CoV research in UAE and the collaboration with CDC 
and other international entities 
• Member of WHO research working group published:  
state of Knowledge and data Gaps of Middle East: Respiratory 
Syndrome Coronavirus ( MERS-CoV) in Humans, November 2013 
• Founder and chair member of the Editorial board for the 
Communicable Diseases Bulletin in Abu Dhabi which is issued quarterly 
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• Participated in the Conferences and Symposiums in the field of 
experience such as: 
 
• Outbreak Response and Management Course 2013 
• Speaker in different conferences during 2012 such as:  
• Vaccine Congress October, 2012 
• 2nd GCC Pediatric Summit Sep,2012 
• Leaders in Health Care, Dubai June 2012 
• Premarital Screening workshop (February,2011) 
• Visa screening Training workshop 2010 
• Series of workshops about Tb management 2010 




Membership in Professional 
Societies 
Member of female Medical student association, FMHS,  
UAEU, 1999-2000 
Member of Emirates Medical Association 2007 
Member of American Public Health Association 2013 
Member of FMHS Alumni 
John Hopkins Bloomberg School of Public Health Alumni 2003 
Member of HIV National Committee, Ministry of Health 2009 




Member of Visa Screening National Committee, MOH 2007 
Member of Home Screening National Committee, MOH 2011 
Member of HAAD Disciplinary Committee, Health Authority Abu Dhabi. 
Chairing Visa Screening Panel, HAAD, Abu Dhabi 
Member of Advisory National Technical Committee for biosecurity,2014 until 
now 
Board member in Rahma Association 2015 until now 
Member of Disciplinary Committee, HAAD from 2009 until now 
Member of Tender Committee HAAD 2012 until now 
 
 
Training and Media Participation • Participated in the planning and implementing of multiple training programs 
such as: 
• Outbreak Response and Management with MOH Oman in Abu Dhabi 2012 
• Influenza Surveillance Workshop in Abu Dhabi 2013 
• Outbreak Response and Management Workshop with EMPHINET in Abu 
Dhabi 2013 
• MERS-CoV training Workshop in 2013  
• Series of Training workshops for Vaccination 2012-2013 
• 2005/2006 Organizer of the Notification of Communicable diseases 
Campaign– GAHS - A.D. UAE 
• 2006  Attended the 1st Annual International infectious disease congress – 
Harvard Medical school Dubai center – Dubai – UAE  
• 2006  Completed MIMMS ( major incident Medical management and support 
) 
• July 2006 Leadership Training Program (Leadership skills, Supervising team 
work, Performance Management, Training skills and motivating employees)   
• 2007 HIV workshop organized by UNDP and the ministry of health, Abu 
Dhabi, UAE 
• 2007 Premarital testing workshop, Dubai, UAE 
• 2007 Implementation of breast screening program workshop ,Abu Dhabi- 
UAE  
• 2008 Dhaman first annual conference – Healthcare Management ,Abu Dhabi- 
UAE 
• 2008-2009 organizer of series of workshops for changing community 
response towards HIV: 
• HIV workshop for media ( Nov.,2008) 
• HIV workshop for Healthcare workers ( Dec.,2008) 




• H1N1 Training: series of workshops for health care workers (June-Nov,2009) 
• H1N1 Training: series of workshops for school professionals (August- 
October,2009) 
• 2010-2011 organizer of series of training workshops 
• Series of workshops about Notification system in HAAD (Dec.,2010) 
• July 2006 Leadership Training Program (Leadership skills, Supervising team 
work, Performance Management, Training skills and motivating employees)   
• Participated in Khatwa show in Abu Dhabi TV in Dec 2011 for HIV awareness 
• Participated in TEDx Al Ain event for Young leaders in 2011 
• Participated in design of the communication plan and the spokesperson in 
Press conferences and media representation in several events such as: 
• Press Conference for Launch of Vaccination Campaign May 2012 
• Press Conference of Adult Vaccination Schedule July 2012 
• Press Conference for Haj & Omra Campaign August,2012 
• Press Conference for School Health  
 
Awards • Best National Academic Performance Award, 1997 
• Mumtaz- Bravo Award, 2009 ( by Health Authority Abu Dhabi) 
• Short listed for the Abu Dhabi Award for Excellence in Government 
Performance/ Category Three/Manager Supervisory Award, 2013 
• Excellence in Teaching Award, UAEU, 2014 




International Collaborations • The lead person of Collaboration between HAAD and CDC for MERS-CoV 
• A member of International Health Regulations network and assigned as Abu 
Dhabi Focal Point  
• A lead person in the Negotiation and MOU between HAAD and EMPHINET. 
• Attended the IHR training workshop in Jordan, Amman 
• A member of the National Delegates for the Inter-country MERS-CoV 
meeting in Cairo, June 2013 
• Active in the Collaboration of HAAD with MOH Oman, arranged the Influenza 
Surveillance workshop in Abu Dhabi in collaboration with MOH Oman 
• Active in the Collaboration of HAAD with MOH Oman, arranged the Outbreak 
Management workshop in Abu Dhabi in collaboration with MOH Oman  
• Active Member in the Collaboration with CDC, USA. Invited them for 
evaluation of the Infectious Diseases e-Notification system 
• A member of the National Delegates for the WHO Sixty-Third World health 
Assembly, Geneva 16-22May. 
• Supervising the collaboration with UNDP for the HIV response plan 
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